Protein matrix vaccines and methods of making and administering such vaccines

ABSTRACT

The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit from U.S. provisional application Ser.No. 60/835,944, filed Aug. 7, 2006 and U.S. provisional application Ser.No. 60/933,764, filed Jun. 8, 2007, the specifications of which arehereby incorporated by reference.

STATEMENT AS TO FEDERALLY FUNDED RESEARCH

This invention was made with Government support under Grant No.U54AI057159 awarded by the National Institutes of Health (NIH). TheGovernment has certain rights in this invention.

BACKGROUND OF THE INVENTION

The invention relates to vaccine compositions, methods of makingvaccines, and methods of vaccine administration.

Many antigens, particularly those associated with a pathogen's capsulelayer stimulate little or no immune response and complicate efforts tocreate effective vaccines against those antigens. Capsules are surfacecomponents of microbes that are typically composed of polymers oforganic compounds such as carbohydrates, amino acids, or alcohols.Capsules are quite diverse chemically. The monomeric units that make upcapsules (e.g., carbohydrates) can be linked together in variousmolecular configurations and can be further substituted with phosphate,nitrogen, sulfate, and other chemical modifications. These chemicalvariations allow capsules to present numerous antigenic targets on themicrobial surface thus allowing escape from the host immune systemdirected at these targets. Capsules can also be virulence factors whichprevent microbes from being phagocytosed and killed by host macrophagesand polymorphonuclear leukocytes. Antibodies against capsules provide apotent defense against encapsulated organisms by fixing complement tothe microbial surface, which can result in their lysis or theiropsonization, uptake, and killing by phagocytic host immune cells. Themost potent antibodies against capsules are IgG antibodies. Capsulesthat fail to induce significant levels of IgG are called T-independentantigens. Covalent coupling of a protein to capsule renders them“T-dependent” and such antigens can elicit an IgG response.

There is a need for safe, synthetically accessible, cost-effectivevaccines directed to capsule and other T-independent antigens that donot evoke strong immune responses or IgG antibody. Such vaccines areneeded to protect against various infectious diseases such as infectionby anthrax, pneumococcus, influenzae Type B, meningococcus, andstreptococcus.

SUMMARY OF THE INVENTION

The present invention relates to vaccine compositions containing anantigen of interest entrapped with a carrier protein in a complex,methods of making such vaccines, and methods of vaccine administration.

Accordingly, in the first aspect, the invention features a vaccinecomposition containing an antigen of interest and a carrier protein,where (i) no more than 50% of the antigen of interest is cross-linked tothe carrier protein and (ii) where the antigen is entrapped with thecarrier protein to form a complex.

In desirable embodiments of the first aspect of the invention, thecomplex has a diameter of between 10 nm and 100 μm. In more desirableembodiments of the first aspect of the invention, the complex has adiameter of about 100 nm to 100 μm. In yet more desirable embodiments ofthe first aspect of the invention, the complex has a diameter of about100 nm to 10 μm.

In other desirable embodiments of the first aspect of the invention, thecomplex, when administered to a mammal, elicits a T-cell dependentimmune response in the mammal.

In additional desirable embodiments of the first aspect of theinvention, the molar ratio of the antigen to the carrier protein isbetween 1 to 10 and 10 to 1. Desirably, the carrier protein is amultimer, for example, a multimer that includes at least 5 subunits. Inother desirable embodiments, the multimer is a homomultimer.

In further desirable embodiments of the first aspect of the invention,the carrier protein is covalently linked to at least one other carrierprotein. Desirably, the covalent linkage contains a peptide bond betweena primary amino group of a lysine side chain and a carboxy group of anaspartate or glutamate side chain. In other desirable embodiments, thecovalent linkage includes a compound of the formula

where R_(n) is a linear or branched alkyl of 1 to 12 carbon atoms, alinear or branched heteroalkyl of 1 to 12 atoms, a linear or branchedalkene of 2 to 12 carbon atoms, a linear or branched alkyne of 2 to 12carbon atoms, an aromatic residue of 5 to 10 carbon atoms, a cyclicsystem of 3 to 10 atoms, —(CH₂CH₂O)_(q)CH₂CH₂— in which q is 1 to 4, ora chemical bond linking two aldehyde groups. In additional desirableembodiments, the covalent linkage contains glutaraldehyde,m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide, orbis-biazotized benzidine. In yet other desirable embodiments, thecovalent linkage contains a bifunctional cross-linker. Desirably, thebifunctional cross-linker is glutaraldehyde,bis[sulfosuccinimidyl]suberate, or dimethyl adipimidate.

In other desirable embodiments of the first aspect of the invention, thecarrier proteins are non-covalently linked. In desirable embodiments,the non-covalent linkage involves a hydrophobic interaction, ionicinteraction, van der Waals interaction, or hydrogen bond.

In additional desirable embodiments of the first aspect of theinvention, the carrier protein is diphtheria toxin or a mutant thereof,diphtheria toxoid, tetanus toxin or a mutant thereof, tetanus toxoid,Pseudomonas aeruginosa exotoxin A or a mutant thereof, cholera toxin Bsubunit, tetanus toxin fragment C, bacterial flagellin (e.g., Vibriocholerae flagellin protein), pneumolysin, an outer membrane protein ofNeisseria menningitidis, Pseudomonas aeruginosa Hcp1 protein,Escherichia coli heat labile enterotoxin, shiga-like toxin (e.g.,Shigella SltB2 protein), human LTB protein, pneumolysin, listeriolysin O(or related proteins), a protein extract from whole bacterial cells(e.g., Pseudomonas aeruginosa or Streptococcal cells), the dominantnegative mutant (DNI) of the protective antigen of Bacillus anthracis,or Escherichia coli beta-galactosidase. In particularly desirableembodiments, the carrier protein is pneumolysin, listeriolysin O,diphtheria toxin, diphtheria toxoid, tetanus toxin, or tetanus toxoid.

In other desirable embodiments of the first aspect of the invention, theantigen of interest is a polysaccharide, a polyalcohol, or a poly aminoacid. Desirably, the polysaccharide contains at least 18 residues. Inother desirable embodiments, the polysaccharide is a Streptococcuspneumoniae polysaccharide, Francisella tularensis polysaccharide,Bacillus anthracis polysaccharide, Haemophilus influenzaepolysaccharide, Salmonella typhi polysaccharide, Salmonella speciespolysaccharide, Shigella polysaccharide, or Neisseria meningitidispolysaccharide. In particularly desirable embodiments, the Streptococcuspneumoniae polysaccharide is any one of capsular type 1-48, e.g., 3, 4,6B, 7A, 7B, 7C, 7F, 9A, 9L, 9N, 9V, 12A, 12B, 12F, 14, 15A, 15B, 15C,15F, 17, 18B, 18C, 19F, 23F, 25A, 25F, 33F, 35, 37, 38, 44, or 46. Inother particularly desirable embodiments, the Francisella tularensispolysaccharide is O antigen.

In further desirable embodiments of the first aspect of the invention,the antigen of interest is a microbial capsular polymer. Desirably, themicrobial capsular polymer is poly-gamma-D-glutamic acid from Bacillusanthracis.

In other desirable embodiments of the first aspect of the invention, theantigen of interest is an organic polymer consisting of monomers havingat least three atoms, where each of the atoms is independently selectedfrom carbon, oxygen, hydrogen, phosphate, nitrogen, and sulfate.Desirably, the organic polymer is derived from a microbe. In otherdesirable embodiments, the organic polymer does not occur in nature.

In additional desirable embodiments, the vaccine composition furtherincludes a second antigen of interest. Desirably the vaccine compositionfurther includes a third antigen of interest.

In the second aspect, the invention features a method of making avaccine composition. This method involves (i) mixing an antigen ofinterest with a carrier protein to form a mixture of the antigen and thecarrier protein and (ii) entrapping the antigen of interest with thecarrier protein, where no more than 50% of the antigen of interest iscross-linked to the carrier protein in the vaccine composition.

In desirable embodiments of the second aspect of the invention, thevaccine composition further includes a pharmaceutically acceptableexcipient.

In other desirable embodiments of the second aspect of the invention,the entrapping involves precipitating the antigen and the carrierprotein from the mixture. Desirably, the precipitating involves a changein pH of the mixture, adding trichloroacetic acid (TCA) or ammoniumsulfate to the mixture, changing the ionic strength of the mixture byincreasing or decreasing the inorganic salt concentration of themixture, heating the mixture to cause the carrier protein and/or theantigen to coagulate, or irradiating the mixture with sufficient flux ofionizing radiation to cause cross-linking.

In desirable embodiments of the second aspect of the invention, themolar ratio of the antigen to the carrier protein is between 1 to 10 and9 to 10 in the vaccine composition.

In additional desirable embodiments of the second aspect of theinvention, the carrier protein is a multimer. Desirably, the multimercontains at least 5 subunits. In other desirable embodiments, themultimer is a homomultimer.

In further desirable embodiments of the second aspect of the invention,the carrier proteins are non-covalently linked. Desirably, thenon-covalent linkage involves a hydrophobic interaction, ionicinteraction, van der Waals interaction, or hydrogen bond.

In additional desirable embodiments of the second aspect of theinvention, the carrier protein is diphtheria toxin or a mutant thereof,diphtheria toxoid, tetanus toxin or a mutant thereof, tetanus toxoid,Pseudomonas aeruginosa exotoxin A or a mutant thereof, cholera toxin Bsubunit, tetanus toxin fragment C, bacterial flagellin (e.g., Vibriocholerae flagellin protein), pneumolysin, listeriolysin O, an outermembrane protein of Neisseria menningitidis, Pseudomonas aeruginosa Hcp1protein, Escherichia coli heat labile enterotoxin, shiga-like toxin(Shigella SltB2 protein), human LTB protein, a protein extract fromwhole bacterial cells (e.g., Pseudomonas aeruginosa or Streptococcalcells), the dominant negative mutant (DNI) of the protective antigen ofBacillus anthracis, or Escherichia coli beta-galactosidase. Inparticularly desirable embodiments, the carrier protein is pneumolysin,listeriolysin O, diphtheria toxin, diphtheria toxoid, tetanus toxin, ortetanus toxoid.

In other desirable embodiments of the second aspect of the invention,the antigen of interest is a polysaccharide, a polyalcohol, or a polyamino acid. Desirably, the polysaccharide contains at least 18 residues.In other desirable embodiments, the polysaccharide is a Streptococcuspneumoniae polysaccharide, Francisella tularensis polysaccharide,Bacillus anthracis polysaccharide, Haemophilus influenzaepolysaccharide, Salmonella typhi polysaccharide, Shigella speciespolysaccharides, Salmonella species polysaccharides, or Neisseriameningitidis polysaccharide. In particularly desirable embodiments, theStreptococcus pneumoniae polysaccharide is any one of capsular type1-48, e.g., 3, 4, 6B, 7A, 7B, 7C, 7F, 9A, 9L, 9N, 9V, 12A, 12B, 12F, 14,15A, 15B, 15C, 15F, 17, 18B, 18C, 19F, 23F, 25A, 25F, 33F, 35, 37, 38,44, or 46. In other particularly desirable embodiments, the Francisellatularensis polysaccharide is O antigen.

In additional desirable embodiments of the second aspect of theinvention, the antigen of interest is a microbial capsular polymer.Desirably, the microbial capsular polymer is poly-gamma-D-glutamic acidfrom Bacillus anthracis.

In yet other desirable embodiments of the first aspect of the invention,the antigen of interest is an organic polymer consisting of monomershaving at least three atoms, where each of the atoms is independentlyselected from carbon, oxygen, hydrogen, phosphate, nitrogen, andsulfate. Desirably, the organic polymer is derived from a microbe. Inother desirable embodiments, the organic polymer does not occur innature.

In further desirable embodiments of the second aspect of the invention,mixing in step (i) involves a second antigen of interest or even a thirdantigen of interest.

In the third aspect, the invention features another method of making avaccine composition. This method involves (i) mixing an antigen ofinterest with a carrier protein and (ii) adding a linker thatcross-links the carrier protein, where no more than 50% of the antigenof interest is cross-linked to the carrier protein in the vaccinecomposition.

In desirable embodiments of the third aspect of the invention, thevaccine composition further includes a pharmaceutically acceptableexcipient. In other desirable embodiments of the third aspect of theinvention, the molar ratio of the antigen to the carrier protein isbetween 1 to 10 and 10 to 1 in the vaccine composition. In additionaldesirable embodiments of the third aspect of the invention, the carrierprotein is a multimer. Desirably, the multimer contains at least 5subunits. In other desirable embodiments, the multimer is ahomomultimer.

In further desirable embodiments of the third aspect of the invention,the method involves reducing a Schiff base in the carrier protein. Inyet further desirable embodiments of the third aspect of the invention,the carrier protein is covalently linked to at least one other carrierprotein. Desirably, the covalent linkage involves a peptide bond betweena primary amino group of a lysine side chain and a carboxy group of anaspartate or glutamate side chain. In other desirable embodiments, thecovalent linkage involves a bifunctional cross-linker. Desirably, thebifunctional cross-linker is glutaraldehyde,bis[sulfosuccinimidyl]suberate, or dimethyl adipimidate.

In additional desirable embodiments of the third aspect of theinvention, the linker is a compound of the formula

where R_(n) is a linear or branched alkyl of 1 to 12 carbon atoms, alinear or branched heteroalkyl of 1 to 12 atoms, a linear or branchedalkene of 2 to 12 carbon atoms, a linear or branched alkyne of 2 to 12carbon atoms, an aromatic residue of 5 to 10 carbon atoms, a cyclicsystem of 3 to 10 atoms, —(CH₂CH₂O)_(q)CH₂CH₂— in which q is 1 to 4, ora chemical bond linking two aldehyde groups.

In other desirable embodiments of the third aspect of the invention, thelinker is glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester,carbodiimide, or bis-biazotized benzidine.

In additional desirable embodiments of the third aspect of theinvention, the carrier protein is diphtheria toxin or a mutant thereof,diphtheria toxoid, tetanus toxin or a mutant thereof, tetanus toxoid,Pseudomonas aeruginosa exotoxin A or a mutant thereof, cholera toxin Bsubunit, tetanus toxin fragment C, bacterial flagellin (Vibrio choleraeflagellin protein), pneumolysin, listeriolysin O, an outer membraneprotein of Neisseria menningitidis, Pseudomonas aeruginosa Hcp1 protein,Escherichia coli heat labile enterotoxin, shiga-like toxin (ShigellaSltB2 protein), human LTB protein, a protein extract from wholebacterial cells (Pseudomonas aeruginosa or Streptococcal cells), thedominant negative mutant (DNI) of the protective antigen of Bacillusanthracis, or Escherichia coli beta-galactosidase.

In further desirable embodiments of the third aspect of the invention,the antigen of interest is a polysaccharide, a polyalcohol, or a polyamino acid. Desirably, the polysaccharide contains at least 18 residues.In other desirable embodiments, the polysaccharide is a Streptococcuspneumoniae polysaccharide, Francisella tularensis polysaccharide,Bacillus anthracis polysaccharide, Haemophilus influenzaepolysaccharide, Salmonella typhi polysaccharide, Shigella speciespolysaccharides, Salmonella species polysaccharides, or Neisseriameningitidis polysaccharide. In particularly desirable embodiments, theStreptococcus pneumoniae polysaccharide is any one of capsular type1-48, e.g., 3, 4, 6B, 7A, 7B, 7C, 7F, 9A, 9L, 9N, 9V, 12A, 12B, 12F, 14,15A, 15B, 15C, 15F, 17, 18B, 18C, 19F, 23F, 25A, 25F, 33F, 35, 37, 38,44, or 46. In other particularly desirable embodiments, the Francisellatularensis polysaccharide is 0 antigen.

In other desirable embodiments of the third aspect of the invention, theantigen of interest is a microbial capsular polymer. Desirably, themicrobial capsular polymer is poly-gamma-D-glutamic acid from Bacillusanthracis.

In yet other desirable embodiments of the third aspect of the invention,the antigen of interest is an organic polymer consisting of monomershaving at least three atoms, where each of the atoms is independentlyselected from carbon, oxygen, hydrogen, phosphate, nitrogen, andsulfate. Desirably, the organic polymer is derived from a microbe. Inadditional desirable embodiments, the organic polymer does not occur innature.

In further desirable embodiments of the third aspect of the invention,mixing in step (i) involves a second antigen of interest or even a thirdantigen of interest.

In the fourth aspect, the invention features a method of vaccinating asubject against an infectious agent. This method involves administeringa vaccine composition of the first aspect of the invention to a subjectin an amount sufficient to induce the production of antibodies in thesubject. In desirable embodiments of the fourth aspect of the invention,the method involves a second administering step where the vaccinecomposition of the first aspect of the invention is administered to thesubject in an amount sufficient to boost the production of antibodies inthe subject. Desirably, in the fourth aspect of the invention, theproduction of antibodies is T-cell dependent. In other desirableembodiments of the fourth aspect of the invention, the production ofantibodies is sufficient to prevent or reduce infection of the subjectby an infectious agent. Desirably, the infectious agent is pneumococcus,meningococcus, Haemophilus influenzae type B, Pseudomonas aeruginosa,Francisella tularensis, Shigella species, Salmonella species,Acinetobacter species, Burkholderia species, or Escherichia coli.

In other desirable embodiments of the fourth aspect of the invention,the method involves a second administering step where a second vaccinecomposition containing an antigen of interest is provided to the subjectin an amount sufficient to boost the production of antibodies in thesubject. Desirably, the production of antibodies is sufficient toprevent or reduce infection of the subject by a second infectious agent.

In desirable embodiments of the fourth aspect of the invention, theantibodies are IgG antibodies. In a further desirable embodiment of thefourth aspect of the invention, the subject is a human.

In desirable embodiments of any one of the aspects of the invention, theStreptococcus pneumoniae polysaccharide is one of capsular typesdescribed in Kong et al. (J. Med. Microbiol. 54:35-356, 2005). Forexample, the Streptococcus pneumoniae polysaccharide capsular typedesirably is 1 (e.g., 1-g or 1-q), 2 (e.g., 2-g, 2-q, or 2-41A), 3(e.g., 3-g, 3-q, 3-c, or 3-nz), 4, 5 (e.g., 5-q, 5-c, 5-qap, or 5-g), 6A(e.g., 6A-g, 6A-cl, 6A-c2, 6A-n, 6A-qap, 6A-6B-g, 6A-6B-q, or 6A-6B-s),6B (e.g., 6B-c, 6A-6B-g, 6A-6B-q, or 6A-6B-s), 7F (e.g., 7F-7A), 7A(e.g., 7A-cn or 7F-7A), 7B (e.g., 7B-40), 7C (e.g., 7C-19C-24B), 8(e.g., 8-g or 8-s), 9A (e.g., 9A-9V), 9L, 9N, 9V (e.g., 9A-9V), 9V and14, 10F (e.g., 10F-q, 10F-ca, or 10F-10C), 10A (e.g., 10A-17A or10A-23F), 10B (e.g., 10B-10C), 11F, 11A (e.g., 11A-nz or 11A-11D-18F),11B (e.g., 11B-11C), 11C (e.g., 11B-11C. or 11C-cn), 11D (e.g.,11A-11D-18F), 12F (e.g., 12F-q or 12F-12A-12B), 12A (e.g., 12A-cn,12A-46, or 12F-12A-12B), 12B (e.g., 12F-12A-12B), 13 (e.g., 13-20), 14(e.g., 14-g, 14-q, 14-v, or 14-c), 15F (e.g., 15F-cn1 or 15F-cn2), 15A(e.g., 15A-ca1, 15A-ca2, or 15A-chw), 15B (e.g., 15B-c, 15B-15C,15B-15C-22F-22A), 15C (e.g., 15C-ca, 15C-q1, 15C-q2, 15C-q3, 15C-s,15B-15C, or 15B-15C-22F-22A), 16F (e.g., 16F-q or 16F-nz), 16A, 17F(e.g., 17F-n and 17F-35B-35C-42), 17A (e.g., 17A-ca or 10A-17A), 18F(e.g., 18F-ca, 18F-w, or 11A-11D-18F), 18A (e.g., 18A-nz or 18A-q), 18B(e.g., 18B-18C), 18C (e.g., 18B-18C), 19F (e.g., 19F-g1, 19F-g2, 19F-g3,19F-q, 19F-n, or 19F-c), 19A (e.g., 19A-g, 19A-, or 19A-ca), 19B, 19C(e.g., 19C-cn1, 19C-cn2, or 7C-19C-24B), (e.g., 13-20), 21 (e.g., 21-caor 21-cn), 22F (e.g., 15B-15C-22F-22A), 23F (e.g., 23F-c, 10A-23F, or23F-23A), 23B (e.g., 23B-c or 23B-q), 24F (e.g., 24F-cn1, 24F-cn2, or24F-cn3), 24A, 24B (e.g., 7C-19C-24B), 25F (e.g., 25F-38), 25A, 27, 28F(e.g., 28F-28A or 28F-cn), 28A (e.g., 28F-28A), 29 (e.g., 29-ca or29-q), 31, 32F (e.g., 32F-32A), 32A (e.g., 32A-cn or 32F-32A), 33F(e.g., 33F-g, 33F-q, 33F-chw, 33F-33B, or 33F-33A-35A), 33A (e.g.,33F-33A-35A), 33B (e.g., 33B-q, 33B-s, or 33F-33B), 33D, 34 (e.g., 34-caor 34s), 35F (e.g., 35F-47F), 35A (e.g., 33F-33A-35A), 35B (e.g.,17F-35B-35C-42), 36, 37 (e.g., 37-g or 37-ca), 38 (e.g., 25F-38), 39(e.g., 39-cn1 or 39-cn2), 40 (e.g., 7B-40), 41F (e.g., 41F-cn or 41F-s),41A (e.g., 2-41A), 42 (e.g., 17B-35B-35C-42), 43, 44, 45, 46 (e.g., 46-sor 12A-46), 47F (e.g., 35F-47F), 47A, 48 (e.g., 48-cn1 or 48-cn2), orGenBank Accession Number AF532714 or AF532715.

DEFINITIONS

By “administering” as used herein in conjunction with a vaccine, ismeant providing to a subject a vaccine in a dose sufficient to induce animmune response in the subject, where the immune response results in theproduction of antibodies that specifically bind an antigen contained inthe vaccine. Administering desirably includes intramuscular injection,intradermal injection, or transcutaneous injection and, desirablyinvolves administration of appropriate immune adjuvants. Administeringmay involve a single administration of a vaccine or administering avaccine in multiple doses. Desirably, a second administration isdesigned to boost production of antibodies in a subject to preventinfection by an infectious agent. The frequency and quantity of vaccinedosage depends on the specific activity of the vaccine and can bereadily determined by routine experimentation.

By “cross-link” is meant the formation of a covalent bond between twomolecules, macromolecules, or combination of molecules, e.g., carrierproteins, either directly, when a “zero-length” linker is used, or byuse of third molecule, the chemical linker, that has two functionalgroups each capable of forming a covalent bond with one of two separatemolecules or between two separate groups in the same molecule (i.e.,these would form “loops” that could also wrap around the polymer).Exemplary linkers include bifunctional linkers which are capable ofcross-linking two carrier proteins. Cross-linking may also occur betweenan antigen and a carrier protein.

By “antigen” as used herein is meant is any molecule or combination ofmolecules that is specifically bound by an antibody or an antibodyfragment.

By “bifunctional linker” as used herein is meant a compound that has twofunctional groups each separately capable of forming a covalent bondwith two separate molecules, atoms, or collections of molecules.Exemplary bifunctional linkers are described, for example, by G. T.Hermanson (Bioconjugate Techniques, Academic Press, 1996) and Dick andBeurret (Conjugate Vaccines. Contribu. Microbiol. Immunol., Karger,Basal 10:48-114, 1989). Desirably a bifunctional linker isglutaraldehyde, bis[sulfosuccinimidyl]suberate, or dimethyl adipimidate.

By a “linker” as used herein is meant a compound or a chemical bond thatcovalently joins two or more molecules. Desirably a linker isglutaraldehyde or a compound of the formula

where R_(n) is a linear or branched alkyl of 1 to 12 carbon atoms, alinear or branched heteroalkyl of 1 to 12 atoms, a linear or branchedalkene of 2 to 12 carbon atoms, a linear or branched alkyne of 2 to 12carbon atoms, an aromatic residue of 5 to 10 carbon atoms, a cyclicsystem of 3 to 10 atoms, —(CH₂CH₂O)_(q)CH₂CH₂— in which q is 1 to 4, ora chemical bond linking two aldehyde groups. Linking may be directwithout the use of a linking molecule. For example, a protein's carboxylgroup may be linked directly to its amino group using carbodiimidechemistry or enymatically using transglutamidases which catalyzecross-linking of this sort.

By “boost the production of antibodies” is meant the activation ofmemory B-cells that occurs during a second exposure to an antigen,called a “booster response,” and is indicative of a long lived“secondary” memory immune response, resulting in the long livedproduction of antibodies.

By “carrier protein” is meant a protein used in a vaccine that invokesan immune response to itself and/or to an antigen complexed with acarrier protein. Desirably the antigen is non-covalently associated withthe carrier protein by being entrapped in a complex with the carrierprotein. Nonetheless, the antigen and the carrier protein may also becovalently linked to each other. Desirably, the carrier protein containsan epitope recognized by a T-cell. Also encompassed by the definition ofa “carrier protein” are multi-antigenic peptides (MAPs), which arebranched peptides. Desirably, a MAP includes lysine. Exemplary desirablecarrier proteins include toxins and toxoids (chemical or genetic), whichmay be mutant. Desirably, a carrier protein is diphtheria toxin or amutant thereof, diphtheria toxoid, tetanus toxin or a mutant thereof,tetanus toxoid, Pseudomonas aeruginosa exotoxin A or a mutant thereof,cholera toxin B subunit, tetanus toxin fragment C, bacterial flagellin,pneumolysin, listeriolysin 0 (and related molecules), an outer membraneprotein of Neisseria menningitidis, Pseudomonas aeruginosa Hcp1 protein,Escherichia coli heat labile enterotoxin, shiga-like toxin, human LTBprotein, a protein extract from whole bacterial cells, the dominantnegative mutant (DNI) of the protective antigen of Bacillus anthracis,or Escherichia coli beta-galactosidase, or any other protein that can becross-linked by a linker.

By “DNI” is meant the dominant negative mutant (DNI) protein, which is amutated form of protective antigen (PA) of B. anthracis, as described byBenson et al. (Biochemistry 37:3941-3948, 1998).

By “entrapped” as used herein in reference to an antigen is meant anantigen that remains in a complex with carrier proteins underphysiological conditions. Desirably, the antigen is entrapped in acomplex with carrier proteins in the absence of significant covalentbonding between the antigen and a carrier protein. Absence ofsignificant covalent bonding, as used herein, refers to no more than 50%of the antigen being covalently bonded to a carrier protein. Desirably,no more than 40%, 30%, 10%, or 5% of the antigen is covalently bonded toa carrier protein.

By “infection” is meant the invasion of a subject by a microbe, e.g., abacterium, fungus, parasite, or virus. The infection may include, forexample, the excessive multiplication of microbes that are normallypresent in or on the body of a subject or multiplication of microbesthat are not normally present in or on a subject. A subject is sufferingfrom a microbial infection when an excessive amount of a microbialpopulation is present in or on the subject's body or when the presenceof a microbial population(s) is damaging the cells or causingpathological symptoms to a tissue of the subject.

By “infectious agent” is meant a microbe that causes an infection.

By “immunogenic” is meant a compound that induces an immune response, ina subject. Desirably, the immune response is a T-cell dependent immuneresponse that involves the production of IgG antibodies.

By “microbe” is meant a bacterium, fungus, parasite, or virus that iscapable of causing an infection in a subject.

By “microbial capsular polymer” is meant a polymer present in or on thecapsule coating of a microbe. Desirably, a microbial capsular polymer isan organic polymer such as a polysaccharide, phosphopolysaccharide,polysaccharide with an amino sugar with a N-acetyl substitution,polysaccharide containing a sulfonylated sugar, another sulfate-modifiedsugar, or phosphate-modified sugar, polyalcohol, poly amino acid,teichoic acid, and an O side chain of a lipopolysaccharide.

By “monomer” is meant a molecular structure capable of forming two ormore bonds with like monomers, often yielding a chain or a series ofbranched, connected chains of repeating monomer substructures, when partof a “polymer.”

By “organic polymer” is meant a polymer composed of covalently linkedmonomers each having three or more of the following atoms: carbon,oxygen, hydrogen, phosphate, nitrogen, and sulfate. Desirably, anorganic polymer is a polysaccharide, phosphopolysaccharide,polysaccharide with an amino sugar with a N-acetyl substitution,polysaccharide containing a sulfonylated sugar, another sulfate-modifiedsugar, or phosphate-modified sugar, sugar, polyalcohol, polyamino acid,teichoic acid, and an O side chain of lipopolysaccharide.

By “polyalcohol” is meant a hydrogenated form of a carbohydrate where acarbonyl group has been reduced to a primary or secondary hydroxylgroup. Exemplary polyalcohols are a polyalkylene oxide (PAO), such as apolyalkylene glycols (PAG), including polymethylene glycols,polyethylene glycols (PEG), methoxypolyethylene glycols (MPEG) andpolypropylene glycols; poly-vinyl alcohol (PVA); polyethylene-co-maleicacid anhydride; polystyrene-co-malic acid anhydride; dektrans includingcarboxymethyl-dextrans; celluloses, including methylcellulose,carboxymethylcellulose, ethylcellulose, hydroxyethylcellulosecarboxyethylcellulose, and hydroxypropylcellulose; hydrolysates ofchitosan; starches such as hydroxyethyl-starches and hydroxypropyl-starches; glycogen; agaroses and derivates thereof; guar gum;pullulan; insulin; xanthan gum; carrageenan; pectin; alginic acidhydrolysates; sorbitol; an alcohol of glucose, mannose, galactose,arabinose, gulose, xylose, threose, sorbose, fructose, glycerol, maltosecellobiose, sucrose, amylose, amylopectin; or mono propylene glycol(MPG).

By “poly amino acid” is meant at least two amino acids linked by apeptide bond. Desirably, a poly amino acid is a peptide containing arepetitive amino acid sequence or a chain of the same amino acid (i.e.,a homopolymer).

By “reducing a Schiff base” is meant exposing azomethine or a compoundof the formula R₁R₂C═N—R₃ (where R₁, R₂, and R₃ are chemicalsubstructures, typically containing carbon atoms) to a reducing agentthat saturates the double bond of the Schiff base with hydrogen atoms.Methods of reducing are known to those skilled in the art.

By “specifically binds” as used herein in reference to an antibody or afragment thereof, is meant an increased affinity of an antibody orantibody fragment for a particular protein, e.g., an antigen, relativeto an equal amount of any other protein. An antibody or antibodyfragment desirably has an affinity for its antigen that is least 2-fold,5-fold, 10-fold, 30-fold, or 100-fold greater than for an equal amountof any other antigen, including related antigens, as determined usingstandard methods such as an enzyme linked immunosorbent assay (ELISA).

By “subject” is meant an animal that can be infected by a microbe.Desirably, a subject is a mammal such as a human, monkey, dog, cat,mouse, rat, cow, sheep, goat, or horse. In a desirable embodiment, thesubject is a human, such as a human child. Desirably, the subject is ahuman infant, toddler, or pre-pubescent child.

By “T-cell independent antigen” is meant an antigen which results in thegeneration of antibodies without the cooperation of T lymphocytes. TheT-cell independent antigen desirably directly stimulates B lymphocyteswithout the cooperation of T lymphocytes. Exemplary desirable T-cellindependent antigens include capsular antigen poly-gamma-D-glutamic acid(PGA), alginic acid (algenate), dextran, polysaccharides (PS), polyamino acids, polyalcohols, and nucleic acids.

Advantages

Compared to existing vaccine technologies, the vaccines of the presentinvention are simple to make, less prone to chemical problems, lessprone to immunological problems, less expensive, more adaptive todifferent antigens of interest and carrier proteins than conjugatetechnology, and more flexible for creating multivalent vaccines(vaccines protective against multiple antigens).

The vaccines of the present invention do not require covalent linkagebetween a carrier protein and the antigen intended to evoke an immuneresponse, thus simplifying the method of making them and reducing thecost of their preparation compared to conjugate vaccine technology.Polysaccharide (PS)-protein conjugate vaccines have been prohibitivelyexpensive to produce and sell in the developing world; conventionalconjugate vaccines are difficult to produce cheaply because of thehighly specialized chemistry required for each vaccine and the costs ofproduction and purification of both PS and carrier protein.

The vaccines of the present invention also address a need for vaccinesthat can safely induce immunity against previously intractable antigens.Such vaccines may be monovalent (having single antigens to induce animmune response) or multivalent (having multiple antigens to inducemultiple immune responses). Vaccines containing TLR (Toll-like receptor)ligands have been shown to evoke immune responses for otherwiseintractable antigens, but they tend to be unsafe because TLR ligands areoften proinflammatory, toxic in even small doses, reactogenic, andlikely to cause adverse symptoms compared to vaccines of the invention.

Other features and advantages of the invention will be apparent from thefollowing Detailed Description, the drawings, and the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic diagram of a non-limiting proposed pathway for theinduction of an anti-PS IgG immune response by a conjugate vaccine for aconjugate made between a PS and the carrier protein tetanus toxoid. Inthis model, only B-cells that display antibody receptors that recognizethe PS bind the PS-protein conjugate. Thus, the carrier protein is boundto the surface of the B-cell that displays the correct PS bindingspecificity.

FIG. 2 is an image of Western blot analysis of PCMV and controlpreparations monitored for cross-linking by SDS polyacryamide gelelectrophoresis and Western blotting with anti-PA antiserum. DNI proteinmigrates at 84 kDa before glutaraldehyde cross-linking. PCVM1-PCMV3(lanes 1-3) show extensive cross-linking of the DNI protein as evidencedby the migration of bands at molecular masses greater than 220 kDa. DNIprotein alone cross-linked in the absence of PGA also shows the samehigh molecular weight species (lane 5). In contrast, DNI mixed with PGAbut not treated with glutaraldehyde shows bands that co-migrate with DNIor lower molecular weight species (lane 4).

FIG. 3 is a graph showing the results of ELISA assays used to measurethe IgM and IgG specific anti-DNI immune responses in mice immunizedwith three PCMV preparations (PCMV1-PCMV3; preparations 1-3) and the twoantigen control preparations 4 and 5. The DNI protein was highlyimmunogenic in all preparations except control preparation 4 which wasnot cross-linked with glutaraldehyde (glut). However, these DNI-specificimmune responses were exclusively IgG-based. While no anti-DNI IgM wasdetected even at day 7 of the immunization, a significant anti-DNI IgGresponse could be detected in mice immunized with PCMV preparations byday 17 and those immunized with cross-linked DNI only (preparation 5). Astrong booster response was noted against DNI on day 30 with allpreparations including preparation 4

FIG. 4 is a graph showing the results of ELISA assays used to measurethe IgM specific anti-PGA immune responses in mice immunized with thethree PCMV preparations (PCMV1-PCMV3; preparations 1-3) and the twoantigen control preparations 4 and 5. Anti-PGA IgM responses showed apattern that was typical of a capsular polymer. The control preparation4 generated a detectable anti-PGA IgM response on day 7 but thisresponse was not boosted on day 17 or day 30. All PCMV preparationsinduced an anti-PGA IgM response on day 7 and then exclusively generatedeven stronger anti-PGA IgM responses on days 17 and 30. As expected thecontrol preparation 5 (cross-linked DNI only) did not generate either anIgM- or IgG-based anti-PGA response

FIG. 5 is a graph showing the results of an ELISA assays used to measurethe IgG specific anti-PGA immune response in mice immunized with thethree PCMV preparations (PCMV1-PCMV3; preparations 1-3) and the twoantigen control preparations 4 and 5. PCMV1-3 generated strong IgG-basedanti-PGA responses that were apparent on day 17 and then clearly boostedon day 30.

FIG. 6 is a graph showing the pooled serum IgM antibody titerpre-immunization and 30 days after immunization with PCMVs containingDNI and alginate (DNI-ALG C, DNI ALG A) and a “one pot” trivalent PCMVpreparation containing DNI complexed with algenate (ALG), dextran (DEX),and PGA.

FIG. 7 is a graph showing the antigen-specific serum IgG antibody titerat 60 days after immunization with PCMVs containing DNI and alginate(DNI-ALG C, DNI ALG A) and a “one pot” trivalent PCMV preparationcontaining DNI complexed with algenate (ALG), dextran (DEX), and PGA.

FIG. 8 is a graph showing the anti-PS IgG antibody titer at 128 daysafter immunization with PCMVs containing DNI and alginate (DNI-ALG C,DNI ALG A) and a “one pot” trivalent PCMV preparation containing DNIcomplexed with algenate (ALG), dextran (DEX), and PGA.

FIGS. 9A and 9B are graphs of IL-6 assays using S. pneumoniaepolysaccharides (pss) obtained from the American Type Culture Collectionand manufactured by Merck or from Serum Institute of India (SII).

FIG. 10 is a graph showing that the contaminant in pss 6B obtained fromSII can be removed using treatment 2 (trt 2; one hour incubation at 80°C. in 1 M NaOH). Treatment 1 (trt 1) is a series of five phenolextractions to remove protein from the polysaccharide.

FIG. 11 is a graph showing that PCMVs containing pss 6B are moreeffective at inducing IgG production than Prevnar®. BSA=Bovine SerumAlbumin; DT=Diphtheria toxin; DTx=Diphtheria toxoid; and TTx=Tetanustoxoid.

FIG. 12 is a graph showing that PCMVs containing pss 6B are as effectiveas Prevnar® at inducing IgM production.

FIG. 13 is a graph showing that PCMVs containing pss 6B are moreeffective at inducing IgG production than Prevnar®.

FIGS. 14-16 are graphs showing that PCMVs containing pss 14 areapproximately equivalent to Prevnar® at inducing IgG production(DTx=Diphtheria toxoid; TTx=Tetanus toxoid).

DETAILED DESCRIPTION

The invention features vaccine compositions and methods of making andadministering such compositions to provide immunity against T-cellindependent antigens or antigens which normally invoke weak immuneresponses, such as, e.g., polysaccharides (PS), polyalcohols, poly aminoacids, and other organic polymers. The vaccines of the invention havethe potent immunological properties of typical PS-protein conjugatevaccines but desirably differ from conjugate vaccines in that nosignificant covalent atomic bonding is required to couple the antigen ofinterest, e.g., PS or capsular organic polymer, to the carrier protein.Rather, the antigen of interest, e.g., PS or capsular organic polymers,is entrapped with the carrier protein. For example, a protein matrix maybe formed by covalent cross-linking carrier protein molecules tothemselves in the presence of soluble antigen, e.g., PS or capsularorganic polymers: these vaccines are referred to as protein matrixvaccines. Carrier proteins that are highly cross-linked to each othercan from a matrix that can capture an antigen and facilitate the uptakeof that antigen and the stimulation of antibody production in immunecells. The carrier protein matrix may be in the form of a “mesh” thatencloses the antigen or a series of “beads on a string” where theantigen is the “string”, the protein or complexes of cross-linkedproteins is the “bead” in this analogy. The antigen is entrapped withthe carrier protein if the carrier protein encircles the antigen to forma ring around the antigen or a 3-dimensional mesh in which the antigenis tangled within. Also, the carrier and the antigen may becross-linked, for instance, by intra-chain cross-links in the antigenchain with the carrier protein. In desirable embodiments, the antigenand the carrier protein are non-covalently linked. Such non-covalentlinkage may involve a hydrophobic interaction, ionic interaction, vander Waals interaction, or hydrogen bond. Non-covalent linkage caninclude physical geometric configurations that non-covalently associateantigen with protein complexes (see: “bead on a string” analogy above).

The carrier protein need not be cross-linked to itself to entrap anantigen. An antigen can also be entrapped by, for example, mixing thecarrier protein and the antigen in an aqueous solution and precipitatingthe carrier protein, thereby co-precipitating the antigen with theprotein. An antigen may also be entrapped with a carrier protein byprecipitating a compound (e.g., alum, sodium hexametaphosphate,polyphosphazene, or other polymers with affinity for proteins driven byhydrophobic or ionic interactions) from a mixture of antigen and carrierprotein. Methods of precipitating proteins are standard in the art andinclude, for example, (1) changing the pH of the mixture, (2) changingthe ionic strength of the solution by increasing or decreasing inorganicsalt concentration of the mixture, (3) or adding trichloroacetic acid(TCA) or ammonium sulfate to the mixture, (4) heating the mixture tocause the protein to coagulate (i.e., form a precipitate or gel), (5)chemically modifying the protein in the mixture in a way that renders itinsoluble, and (6) irradiating the protein solution with a sufficientflux of ionizing radiation (ultraviolet, gamma, or beta rays) as tocause cross-linking and/or precipitation of the protein, among others.

When a capsular protein of a pathogen is used, such vaccines are termedprotein capsular matrix vaccines (PCMV). As described in the Examples,PCMVs were produced including ones based on the model T-independentcapsular antigen, poly-gamma-D-glutamic acid (PGA), as well as alginicacid (algenate) and dextran, and the exemplary carrier protein, DNI. ThePGA PCMV was simple to make in large quantity and was found to induceimmune responses typical of PGA-protein conjugate vaccines. Vaccines ofthe invention may be prepared using any of many possible linkers tocross-link any of many possible carrier proteins in the presence of anyantigen of interest. Exemplary and preferred linkers, carrier proteins,and antigens of interest are discussed herein.

Polysaccharides (PS) are polymers of saccharides (sugars). PS derivedfrom capsules are the primary antigenic components involved inprotective immunity against encapsulated bacterial pathogens such asNeisseria meningitidis, Streptococcus pneumoniae, Salmonella typhi, andHaemophilus influenzae Type B. Immunization of adolescents and adultswith vaccines based on microbial PS has been successful in reducingdisease burden, but has proven less effective in providing protectiveimmunity to infants and young children (i.e., children less than 24months of age). Young children have not yet developed a mature adaptiveimmune repertoire and T cell-independent antigens such as capsular PSare poorly immunogenic and do not lead to long-term protective immuneresponses (i.e., an immunological memory response) in such young vaccinerecipients.

A T-cell independent antigen such as PS can be converted to a T-celldependent antigen by chemical coupling of PS to protein; this process iscalled “conjugation” and involves the formation of covalent bondsbetween atoms in the PS structure and side chain atoms of amino acidspresent in the “carrier” protein. Such “conjugate vaccines” moreefficiently promote the induction of B-cell maturation and isotypeswitching leading to much higher levels of antibody with the correctanti-PS protective profile. Protective antibodies have high affinity fortheir PS antigens, and typically are of the Immunoglobulin G (IgG)subclass, a long-lived antibody with complement fixing and opsoniceffector activity.

An exemplary, non-limiting pathway for induction of an anti-PS IgGimmune response by a conjugate made between a PS and the carrier proteintetanus toxoid is shown in FIG. 1. In this model, only B-cells thatdisplay antibody receptors that recognize the PS bind the PS-proteinconjugate. Thus, the carrier protein is bound to the surface of theB-cell that displays the correct PS binding specificity. The protein-PScomplex is taken up by these B-cells into the intracellular vacuolarcompartment where the carrier is processed by proteolytic degradation.Peptides derived from the carrier protein are transported and loadedinto the presentation groove of the MHC-Class II receptor (MHC-II). ThisMHC-II-carrier peptide complex is displayed on the surface of theB-cell. Upon recognition of the MHC-II-peptide complex by the T-cellreceptor (TCR), T-cells become activated and secrete cytokines thatprovide “help” for the induction of B-cell differentiation. B-cellsexpand in numbers and differentiate into “plasma cells” which nowsecrete antibody. Initially Immunoglobulin M (IgM) is produced by plasmacells but eventually the T-cell help causes the plasma cells to classswitch and produce other isotype classes of antibody such as IgG. Thisprocess continues with plasma cells undergoing mutational changesleading to production of antibody receptors that have even higheraffinity for the PS-protein conjugates. As antigen is cleared, only thehigher affinity plasma cells are activated by residual PS-proteinconjugate remaining in circulation. The process of T-cell dependentmaturation of plasma cells continues, leading to the expansion of plasmacell populations which produce high affinity antibodies of the IgGclass. The expansion can be easily monitored by measuring the levels ofanti-PS IgG antibodies in the serum of an immunized subject, e.g., ahuman.

Eventually the maturation and switching process leads to the productionof Memory B-cells which are long lived and specific for the PS. MemoryB-cells have a unique property in that they can be immediately activatedif exposed to PS. Activation causes Memory B-cells to multiply andquickly produce anti-PS IgG. The activation of memory B cells thatoccurs during a second exposure of to PS antigen is called a “boosterresponse” and is indicative of a long lived “secondary” memory immuneresponse. Primary immunization may stimulate the production of IgMantibodies and some IgG antibodies. Upon secondary immunization, i.e.,the “booster” shot, memory cells already programmed by the firstimmunization are stimulated to produce large quantities of IgG, thememory immune response.

A T-cell independent antigen generally does not stimulate lastingimmunity, i.e., the production of IgG antibodies, but may stimulate theproduction of less potent and more temporary IgM antibodies. As such, PSantigens alone do not typically produce booster responses of IgG.However, PS do produce booster responses if primary immunization isperformed with a PS-protein conjugate because memory cells induced bythe conjugate have already been programmed to produce IgG. Indeed, thebooster response in vaccinated animals or humans is thought to mimic theprotective response due to exposure to a microbe displaying the PS; thislong term memory is critical for a vaccine to work in protectingimmunized subjects years after their immunization with conjugatevaccines. Thus, PS-protein conjugates are valued for (1) their abilityto induce high levels of IgG against PS antigens, and (2) their abilityto induce memory immune responses against PS antigens. PS antigenstypically do not display these properties and thus are inferiorantigens. The difficulty in synthesizing conjugate vaccines and theircost of production has slowed the development of conjugate vaccines formany bacterial diseases where an immune response to PS may beprotective.

Other T-cell independent antigens include homopolymers of amino acids,such as poly-gamma-D-glutamic acid (PGA), and polyalcohols. Indeed mostbiological polymers are T-cell independent antigens. Polymers cancrosslink Immunoglobulin (Ig) receptors on B-cells that recognize themdue to the repetitive nature of their chemical structures (and thusepitopes). Thus polymers can activate B-cells for production ofanti-polymer IgM in the same way that polysaccharides do. For example,an amino acid homopolymer, poly-gamma-D-glutamic acid (PGA) of Bacillusanthracis, is a capsular polymer that is poorly immunogenic and also aT-cell independent antigen. Vaccines composed of PGA conjugated toprotein carriers are highly immunogenic, able to induce anti-PGA IgG,and immunological memory to PGA. Hence, most polymers respond like PS interms of their immunogenicity because they cannot be processed anddisplayed in the context of MHC-II and thus cannot recruit T-cell help.An exception is found in some naturally-occurring polymers that interactwith another class of receptor termed Toll-like receptors (TLRs). Onceactivated, TLRs can induce production of cytokines by host cells andproduce changes in the adaptive immune response. Some PS are covalentlyattached to TLR ligands or contaminated with such ligands. For example,lipopolysaccharides (LPS) are PS that are highly immunogenic and induceIgG and memory responses; the lipid A moiety of LPS is a TLR ligand andmay be responsible for the immunological properties.

In another example, a few pneumococcal PS have been found to displaysome of the immunological properties of conjugate vaccines in that theyinduce isotype switching to IgG even if they are not attached to aprotein carrier. Recently, the commercial polysaccharide vaccinePneumovax-23, as well as individual PS from various strains ofStreptococcus pneumoniae, were found to be contaminated with TLR ligands(Sen et al., J. Immunol. 175:3084-3091, 2005). This finding may explainwhy these PS preparations can induce isotype switching to IgG in theabsence of protein conjugation. These pneumococcal PS induced IL-6 andTNF-α secretion by macrophages. However, further purification of the PSby phenol extraction abrogated cytokine secretion from macrophages. Inimmunization studies, the phenol extracted PS were poorly immunogenicand no longer induced an anti-PS IgG. Thus, phenol extraction removescontaminating molecules that were responsible for these unusualimmunogenic properties of this PS preparation. The contaminatingmolecules appear to be TLR ligands given their ability to activateTLR-dependent cytokine responses in macrophages. Further purification ofthe PS by phenol extraction removed the contaminating TLR ligands andrendered the PS totally T-cell independent.

The above example illustrates that PS antigen can act like conjugatePS-protein antigens without covalent coupling of protein tocarbohydrate. Unfortunately, TLR ligands are usually proinflammatory.For example, LPS is toxic in even small doses. Thus, while mixing a TLRligand with a PS might broaden the immune response to the PS, thisapproach is also likely to produce vaccine that is reactogenic andlikely to cause adverse symptoms in vaccine recipients. Conjugatevaccine technology remains the method of choice for production of PSvaccine with the desired spectrum of immunogenicity and safety.

The development of PS-protein conjugate vaccines has greatly reduced thechildhood disease burden caused by invasive bacterial pathogens. Ahandful of such vaccines including ones against Haemophilus influenzaeType B and certain strains of meningococci and streptococci arecommercially available in the developed world. These PS-proteinconjugate vaccines are prohibitively expensive to produce and sell inthe developing world. For example, the commercially available 7-valentpneumococcal conjugate vaccine costs about $58 (2006 U.S. dollars) perdose and requires a four-dose regimen. The cost alone puts this vaccineout of the reach of those in developing countries that carry the burdenof the disease.

Conventional conjugate vaccines are difficult to produce cheaply becauseof the chemistry involved and the costs of production and purificationof both PS and carrier protein. Usually both need to be quite purebefore conjugation chemistry can be performed with a reasonable couplingefficiency. Typically, coupling chemistry must be worked out for variousPS that is unique for the chemistry of the PS and the carrier proteinsthat have been selected. This coupling chemistry introduces functionalgroups in the PS that then can be linked to carrier protein typicallythrough the epsilon amino side chains of lysine residues. The chemicalmodification of PS to introduce such coupling groups can destroyepitopes on the PS and introduce new epitopes (e.g., associated with thelinker or modified saccharide groups) whose significance can only beassessed by performing careful immunological analysis. Furthermore, forconventional PS-protein conjugate vaccines, the size of the PS, thenumber of PS molecules bound per protein carrier molecule, the nature ofthe carrier selected, and the type of linkage chemistry can all affectimmunogenicity of the conjugate vaccine. As such, for example, in thecase of pneumococcal disease where each of the 90+ known serotypes has adifferent PS structure (Bentley et al., PLOS Genetics 2(3):e31 262-269,2006), one single conjugation method may not be appropriate for allserotypes. Reproducibly synthesizing conjugate vaccines withreproducible immunological properties involves careful control of thesize of the PS, the number of PS molecules bound per protein carriermolecule, the nature of the carrier selected, and the type of linkagechemistry and this, in turn, dramatically increases the cost ofmanufacture of conjugate vaccines.

The emergence of antibiotic resistance highlights the urgency for thedevelopment of safe and effective vaccines. Making vaccines widelyavailable, especially for those in developing countries, requires thatthe manufacture of vaccines also to be cost-effective. Incorporation ofcombined conjugate vaccines against many polysaccharide antigens fromdifferent serotypes of one or more bacterial species into the childhoodimmunization regimen would simplify vaccine administration in thathigh-risk population. However, current conjugate vaccine technology isnot cost-effective and thus, combination conjugate vaccines arevirtually impossible to deliver to the developing world. Indeed even inthe developed world with its strong established markets, the recentsupply shortage of the Wyeth 7-valent conjugate pneumococcal vaccineillustrates how difficult it is to produce and stockpile a vaccine thatrequires complex conjugate vaccine synthetic technology.

In desirable embodiments, the vaccines of the invention are polyvalentcapsular matrix vaccines (PCMV) where one or more bacterial capsularcomponents are entrapped in a polyvalent carrier protein matrix. PCMVscan be produced easily because one needs as a starting material theantigen of interest, e.g., capsules, that are only moderately pure. Forexample, Vedan poly gamma-D-glutamic acid (PGA) is not pure (it carrieda protease active on DNI) yet, as described herein, it performed exactlyas expected for a T-cell independent antigen (Example 1). Incorporationof PGA into a PCMV was successful in all three PCMV preparations thatvaried in their protein-to-PGA ratios over a 7-fold range.

Because the method of making vaccines of the invention does not requireany knowledge of the chemistry of the antigen of interest, e.g., thecapsule polysaccharide, the method does not depend on the need todevelop cross-linking chemistry that is compatible with the chemistry ofthe antigen of interest and the carrier protein. While it is possiblethat some antigens may nonetheless interact with the linker, this shouldnot detract from the efficacy of the vaccine, because the unintendedcross-linking of the antigen of interest and the carrier protein wouldbe expected to have immunogenic properties anyway. In the vaccines ofthe invention, cross-linking of the antigen of interest to the carrierprotein is not a requirement for the vaccine to be effective. This is insharp contrast to conventional conjugate vaccines, which are thushampered in their manufacture and development. The vaccines of theinvention desirably have at least, e.g., 1%, 5%, 10%, 20%, 30%, 40%,50%, 60%, 70%, 80%, 90%, 95%, 98%, or even 100% of the carrier proteinscross-linked and no more than, e.g., 1%, 5%, 10%, 15%, 20%, 30%, 40%,50%, 60%, 70%, 80%, or 90% of the antigen of interest is cross-linked tothe carrier protein. Desirably, no more than 10% of antigens arecross-linked to the carrier proteins and at least 50% of carrierproteins are cross-linked.

The methods of making vaccines described herein do not result in theextensive modification of the antigen of interest, e.g., a capsularpolymer. The antigen generally remains in the same state with a possiblemodification being, e.g., the reduction of reducing sugars for PScapsules that carry such groups at the end of the polymer chains. Suchminor modifications are unlikely to affect immunogenicity of mostcapsular PS because the end sugars are 100-10000× less abundant than theinternal residues in the polymer. In contrast, for conventionalconjugate vaccines, it is usually necessary to introduce linker groupsinto the antigen, e.g., a capsular polymer, that serve as the point ofcovalent attachment of the carrier protein. Linkers need to be usedbecause many antigens, e.g., capsular polymers, do not have a reactivegroup such as a carboxyl or amino group as part of their structure. Forexample, the introduction of linker chemistry into a PS can result indestruction of capsular epitopes and generation of novel epitopes thatmight be undesirable in a vaccine product because of their unknownimmunological cross-reactivity with host self-epitopes.

The methods of making vaccines described herein are less complex thanconjugate vaccine technology because its chemistry depends only on thecross-linking chemistry of the carrier protein (e.g., DNI, cholera toxinB subunit, diphtheria toxin, tetanus toxin Fragment C, or Escherichiacoli beta-galactosidase). For example, while the capsular polymeraffects the rate of cross-linking when mixed with DNI, it does notaffect the pattern or extent of cross-linking which is governed more bythe protein being used, its concentration, and the concentration of thecross-linking agent (e.g., glutaraldehyde) added. These parameters canreadily be adjusted, thereby reducing the time and effort required tomake the vaccine, and saving expense.

The methods of making PCMV vaccines described herein can be used withany antigen, e.g., any capsular polymer or any polymer with few if anyamino groups, and any carrier protein that can be cross-linked, e.g.,carrier proteins not having critical epitopes that can be destroyed byborohydride reduction. Carrier proteins that may be used in the methodsdescribed herein desirably have at least 2 lysine residues or otherresidues that are unblocked and that can be cross-linked by chemicalmodification. Tetanus toxoid is one possible carrier protein. This toxinis detoxified by treatment with formaldehyde, a reagent that reacts withamino groups of proteins. Other desirable carrier proteins include thecholera toxin B subunit (available from SBL Vaccin AB), diphtheriatoxin, tetanus toxin Fragment C (available from Sigma Aldrich), DNI, orbeta-galactosidase from Escherichia coli (available from Sigma Aldrich).

Current multivalent conjugate vaccines are made by synthesis ofindividual conjugate vaccines first, followed by their mixing to producea “cocktail” conjugate vaccine (e.g., the Wyeth hepta-valentpneumococcal vaccine, Prevnar®). The present invention's methods ofmaking vaccines can be used to make multivalent vaccines by mixingchemically different antigens, e.g., capsular organic polymers, togetherbefore cross-linking the carrier protein, e.g., with glutaraldehyde, orby mixing specific vaccines of the invention that were synthesizedseparately. This flexibility provides significant advantages over thepresent methods of manufacturing multivalent vaccines.

Exemplary vaccines of the invention discussed in the examples, PCMVvaccines #1-3, performed like conjugate vaccine despite the fact thatthese vaccines were synthesized by a method that is not predicted togenerate any covalent bonds between atoms making up the PGA molecule andDNI protein. Glutaraldehyde reacts exclusively with amino side chains ofproteins typified by the epsilon amino group of lysine residues. The PGApolymer contains no free amino groups and possesses only carboxylside-chains which do not react with glutaraldehyde. Thus, theconjugate-like immune responses generated by PCMVs indicate that longPGA molecules were molecularly entrapped within a cross-linked matrix ofDNI protein molecules.

According to a non-limiting model, the entrapment acts to carry DNIprotein and PGA into B-cells that bind such matrixes by virtue of Igreceptors that recognize PGA immunologically. Once taken up inside theseB cells, the matrixes are degraded in a manner similar to conventionalconjugate vaccines and that this results in DNI-derived peptides thatare displayed on MHC-II molecules of the corresponding B-cells. This inturn recruits T-cell help and thus leads to the expansion and maturationof such B cells to become IgG producing plasma and memory cells specificfor PGA. Thus, according to the non-limiting model PCMVs work likeprotein-conjugate capsular vaccines immunologically but are distinctbecause PCMVs lack significant covalent bonding between the carrierprotein and the capsular polymers.

The vaccines of the invention, including PCMVs, may be used incombination, for example, in pediatric vaccines. In addition, thevaccines of the invention may be used to vaccinate against, for example,Pneumococcus infection, Streptococcus (groups A and B) infection,Haemophilus influenzae type B (“HiB”) infection, meningococcal (e.g.,Neisseria meningitides) infection, and may be used as O antigen vaccinesfrom Gram negative bacteria (e.g., Pseudomonas aeruginosa, Francisellatularensis (Thirumalapura et al., J. Med. Microbiol. 54:693-695, 2005;Vinogradov and Perry, Carbohydr. Res. 339:1643-1648, 2004; Vinogradov etal., Carbohydr. Res. 214:289-297, 1991), Shigella species, Salmonellaspecies, Acinetobacter species, Burkholderia species, and Escherichiacoli).

Vaccines of the invention may be made using any linkers, such as, e.g.,those described herein, to cross-link any carrier protein, such as,e.g., those described herein, in the presence of one or more antigens ofinterest, such as, e.g., those described herein. If one antigen ofinterest is used, the protein matrix vaccine of the invention is said tobe monovalent. If more than one antigen of interest is used, the proteinmatrix vaccine of the invention is said to be multivalent. If amicrobial capsular polymer is the antigen of interest, the proteinmatrix vaccine of the invention is said to be a protein capsular matrixvaccine (PCMV).

Linkers

Cross-linking carrier proteins are well known in the art and includeglutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester,carbodiimide, and bis-biazotized benzidine.

General methods and moieties for directly cross-linking carrierproteins, using a homobifunctional or a heterobifunctional linkers aredescribed, for example, by G. T. Hermanson in Bioconjugate Techniques,Academic Press, 1996 and Dick and Beurret in Conjugate Vaccines.Contribu. Microbiol. Immunol., Karger, Basal 10:48-114, 1989. Forexample, with a carrier protein possessing n number of lysine moieties,there are, theoretically, n+1 primary amines (including the terminalamine) available for reaction with an exemplary cross-linker'scarboxylic group. Thus, using this direct conjugation procedure theproduct is limited to having n+1 amide bonds formed.

The linker employed in desirable embodiments of the present inventionis, at its simplest, a bond connecting two carrier proteins. The linkercan be, a linear, cyclic, or branched molecular skeleton, with pendantgroups which bind covalently to two carrier proteins, (A) and (B). Anygiven carrier protein may be linked to more than one carrier protein,such that a matrix of interconnected carrier proteins is created, inwhich an antigen may be enclosed.

The term linkage group refers to the covalent bond that results from thecombination of reactive moieties of linker (L) with functional groups of(A) or (B). Examples of linkage groups include, without limitation,ester, carbamate, thioester, imine, disulfide, amide, ether, thioether,sulfonamide, isourea, isothiourea, imidoester, amidine, phosphoramidate,phosphodiester, thioether, and hydrazone.

The linking of (A) with (B) is achieved by covalent means, involvingbond (linkage group) formation with one or more functional groupslocated on (A) and (B). Examples of chemically reactive functionalgroups which may be employed for this purpose include, withoutlimitation, amino, hydroxyl, sulfhydryl, carboxyl, carbonyl, thioethers,guanidinyl, imidazolyl, and phenolic groups, all of which are present innaturally-occurring amino acids in many carrier proteins.

The covalent linking of (A) with (B) may therefore be effected using alinker (L) which contains reactive moieties capable of reaction withsuch functional groups present in (A) and (B). The product of thisreaction is a linkage group which contains the newly formed bondslinking (L) with (A) and (L) with (B). For example, a hydroxyl group of(A) may react with a carboxylic acid group of (L), or an activatedderivative thereof, vide infra, resulting in the formation of an esterlinkage group.

Examples of moieties capable of reaction with sulfhydryl groups includeα-haloacetyl compounds of the type XCH₂CO— (where X=Br, Cl, or I), whichshow particular reactivity for sulfhydryl groups, but which can also beused to modify imidazolyl, thioether, phenol, and amino groups asdescribed by, for example, Gurd, Methods Enzymol. 11:532, 1967.N-Maleimide derivatives are also considered selective towards sulfhydrylgroups, but may additionally be useful in coupling to amino groups undercertain conditions. Reagents such as 2-iminothiolane (Traut et al.,Biochemistry 12:3266, 1973), which introduce a thiol group throughconversion of an amino group, may be considered as sulfhydryl reagentsif linking occurs through the formation of disulphide bridges.

Examples of reactive moieties capable of reaction with amino groupsinclude, for example, alkylating and acylating agents. Representativealkylating agents include:

(i) α-haloacetyl compounds, which show specificity towards amino groupsin the absence of reactive thiol groups and are of the type XCH₂CO—(where X=Cl, Br or D as described by, for example, Wong (Biochemistry24:5337, 1979);

(ii) N-maleimide derivatives, which may react with amino groups eitherthrough a Michael type reaction or through acylation by addition to thering carbonyl group as described by, for example, Smyth et al. (J. Am.Chem. Soc. 82:4600, 1960 and Biochem. J. 91:589, 1964);

(iii) aryl halides such as reactive nitrohaloaromatic compounds;

(iv) alkyl halides, as described by, for example, McKenzie et al. (J.Protein Chem. 7:581, 1988);

(v) aldehydes and ketones capable of Schiff's base formation with aminogroups, the adducts formed usually being stabilized through reduction togive a stable amine;

(vi) epoxide derivatives such as epichlorohydrin and bisoxiranes, whichmay react with amino, sulfhydryl, or phenolic hydroxyl groups;

(vii) chlorine-containing derivatives of s-triazines, which are veryreactive towards nucleophiles such as amino, sulfhydryl, and hydroxylgroups;

(viii) aziridines based on s-triazine compounds detailed above asdescribed by, for example, Ross (J. Adv. Cancer Res. 2:1, 1954), whichreact with nucleophiles such as amino groups by ring opening;

(ix) squaric acid diethyl esters as described by, for example, Tietze(Chem. Ber. 124:1215, 1991); and

(x) α-haloalkyl ethers, which are more reactive alkylating agents thannormal alkyl halides because of the activation caused by the etheroxygen atom, as described by, for example, Benneche et al. (Eur. J. Med.Chem. 28:463, 1993).

Representative amino-reactive acylating agents include:

(i) isocyanates and isothiocyanates, particularly aromatic derivatives,which form stable urea and thiourea derivatives respectively;

(ii) sulfonyl chlorides, which have been described by, for example,Herzig et al. (Biopolymers 2:349, 1964);

(iii) acid halides;

(iv) active esters such as nitrophenylesters or N-hydroxysuccinimidylesters;

(v) acid anhydrides such as mixed, symmetrical, or N-carboxyanhydrides;

(vi) other useful reagents for amide bond formation as described by, forexample, M. Bodansky (Principles of Peptide Synthesis, Springer-Verlag,1984);

(vii) acylazides, e.g., where the azide group is generated from apreformed hydrazide derivative using sodium nitrite, as described by,for example, Wetz et al. (Anal. Biochem. 58:347, 1974); and

(viii) imidoesters, which form stable amidines on reaction with aminogroups as described by, for example, Hunter and Ludwig (J. Am. Chem.Soc. 84:3491, 1962).

Aldehydes, such as, e.g., glutaraldehyde, and ketones may be reactedwith amines to form Schiff's bases, which may advantageously bestabilized through reductive amination. Alkoxylamino moieties readilyreact with ketones and aldehydes to produce stable alkoxyamines asdescribed by, for example, Webb et al. (Bioconjugate Chem. 1:96, 1990).

Examples of reactive moieties capable of reaction with carboxyl groupsinclude diazo compounds such as diazoacetate esters and diazoacetamides,which react with high specificity to generate ester groups as describedby, for example, Herriot (Adv. Protein Chem. 3:169, 1947). Carboxylicacid modifying reagents such as carbodiimides, which react throughO-acylurea formation followed by amide bond formation, may also beemployed.

The functional groups in (A) and/or (B) may, if desired, be converted toother functional groups prior to reaction, for example, to conferadditional reactivity or selectivity. Examples of methods useful forthis purpose include conversion of amines to carboxylic acids usingreagents such as dicarboxylic anhydrides; conversion of amines to thiolsusing reagents such as N-acetylhomocysteine thiolactone,S-acetylmercaptosuccinic anhydride, 2-iminothiolane, or thiol-containingsuccinimidyl derivatives; conversion of thiols to carboxylic acids usingreagents such as α-haloacetates; conversion of thiols to amines usingreagents such as ethylenimine or 2-bromoethylamine; conversion ofcarboxylic acids to amines using reagents such as carbodiimides followedby diamines; and conversion of alcohols to thiols using reagents such astosyl chloride followed by transesterification with thioacetate andhydrolysis to the thiol with sodium acetate.

So-called zero-length linkers, involving direct covalent joining of areactive chemical group of (A) with a reactive chemical group of (B)without introducing additional linking material may, if desired, be usedin accordance with the invention. Examples include compounds in which(L) represents a chemical bond linking an oxygen atom of (A) to acarbonyl or thiocarbonyl moiety present in (B), such that the linkagegroup is an ester or thioester. For example, an amino group (A) can belinked to a carboxyl group (B) by using carbodiimide chemistry yieldingA-L-B where L is a amide bond or R—C═O linked to N—R where R is thecarbon chain derived from amino acid side chains of the same or twodifferent protein molecules.

Most commonly, however, the linker includes two or more reactivemoieties, as described above, connected by a spacer element. Thepresence of a spacer permits bifunctional linkers to react with specificfunctional groups within (A) and (B), resulting in a covalent linkagebetween these two compounds. The reactive moieties in a linker (L) maybe the same (homobifunctional linker) or different (heterobifunctionallinker, or, where several dissimilar reactive moieties are present,heteromultifunctional linker), providing a diversity of potentialreagents that may bring about covalent attachment between (A) and (B).

Spacer elements typically consist of chains which effectively separate(A) and (B) by a linear or branched alkyl of 1 to 10 carbon atoms, alinear or branched heteroalkyl of 1 to 10 atoms, a linear or branchedalkene of 2 to 10 carbon atoms, a linear or branched alkyne of 2 to 10carbon atoms, an aromatic residue of 5 to 10 carbon atoms, a cyclicsystem of 3 to 10 atoms, or —(CH₂CH₂O)_(n)CH₂CH₂—, in which n is 1 to 4.

The nature of extrinsic material introduced by the linking agent mayhave a bearing on the pharmacokinetics and/or activity of the ultimatevaccine product. Thus it may be desirable to introduce cleavablelinkers, containing spacer arms which are biodegradable or chemicallysensitive or which incorporate enzymatic cleavage sites.

These cleavable linkers, as described, for example, in PCT PublicationWO 92/17436 (hereby incorporated by reference), are readily biodegradedin vivo. In some cases, linkage groups are cleaved in the presence ofesterases, but are stable in the absence of such enzymes. (A) and (B)may, therefore, advantageously be linked to permit their slow release byenzymes active near the site of disease.

Linkers may form linkage groups with biodegradable diester, diamide, ordicarbamate groups of formula I:-(Z¹)_(o)-(Y¹)_(u)-(Z²)_(s)-(R₁₁)-(Z³)_(t)-(Y²)_(v)-(Z⁴)_(p)-where, each of Z¹, Z², Z³, and Z⁴ is independently selected from O, S,and NR₁₂ (where R₁₂ is hydrogen or an alkyl group); each of Y¹ and Y² isindependently selected from a carbonyl, thiocarbonyl, sulphonyl,phosphoryl or similar acid-forming group; o, p, s, t, U, and v are eachindependently 0 or 1; and R₁₁ is a linear or branched alkyl of 1 to 10carbon atoms, a linear or branched heteroalkyl of 1 to 10 atoms, alinear or branched alkene of 2 to 10 carbon atoms, a linear or branchedalkyne of 2 to 10 carbon atoms, an aromatic residue of 5 to 10 carbonatoms, a cyclic system of 3 to 10 atoms, —(CH₂CH₂O)_(q)CH₂CH₂— in whichq is 1 to 4, or a chemical bond linking -(Z³)_(o)-(Y¹)_(u)-(Z²)_(s)- to-(Z¹)_(t)-(Y²)_(v)-(Z⁴)_(p)-.

Exemplary desirable linkers (L) used in the present invention may bedescribed by any of formulas II-III:

where the linker is covalently attached to both an oxygen atom (A) andan oxygen atom of (B). Accordingly, linker (L) of formulas II-III areattached to carrier proteins (A) and (B) via dipyran, ester, orcarbamate linkage groups. In these embodiments, R₁₃ represents a linearor branched alkyl of 1 to 10 carbon atoms, a linear or branchedheteroalkyl of 1 to 10 atoms, a linear or branched alkene of 2 to 10carbon atoms, a linear or branched alkyne of 2 to 10 carbon atoms, anaromatic residue of 5 to 10 carbon atoms, a cyclic system of 3 to 10atoms, —(CH₂CH₂O)_(n)CH₂CH₂— in which n is 1 to 4, or a chemical bondlinking two nitrogens or two carbonyls.

Linkers designed to form hydrazone linkages have the chemical formulaIV:

where Z⁵ is selected from O, S, or NR₁₆; R₁₆ is hydrogen or an alkylgroup; R₁₅ is selected from hydrogen, an alkyl, or a heteroalkyl; Y³ isselected from a carbonyl, thiocarbonyl, sulphonyl, phosphoryl, or asimilar acid-forming group covalently bound to an oxygen atom of (A); wis 0 or 1; R₁₄ is a linear or branched alkyl of 1 to 10 carbon atoms, alinear or branched heteroalkyl of 1 to 10 atoms, a linear or branchedalkene of 2 to 10 carbon atoms, a linear or branched alkyne of 2 to 10carbon atoms, an aromatic residue of 5 to 10 carbon atoms, a cyclicsystem of 3 to 10 atoms, —CH₂CH₂O)_(n)CH₂CH₂—, in which n is 1 to 4, ora chemical bond linking —(Y³)-(Z⁵)_(w)— to

and X₄ is a hydrazone resulting from the condensation reaction of (B)containing a hydrazide group and the precursor to linker II, in which X₄is the oxygen atom of a ketone or aldehyde group.Carrier Proteins

In general, any carrier protein that can be entrapped with an antigenunder physiological conditions may be used in the present invention.Desirably, the antigen is entrapped in a complex with carrier proteinsin the absence of significant covalent bonding between the antigen and acarrier protein. Absence of significant covalent bonding, refers to nomore than 50% of the antigen being covalently bonded to a carrierprotein. In desirable embodiments, no more than 40%, 30%, 10%, or 5% ofthe antigen is covalently bonded to a carrier protein. Theantigen/carrier protein complex may contain another compound, such asalum, and this other compound, in desirable embodiments, can entrap theantigen and carrier protein.

Carrier proteins used in the vaccines of the invention desirably areproteins that, either alone or in combination with an antigen, invoke animmune response in a subject. Desirably, the carrier protein contains atleast one epitope recognized by a T-cell. Desirably, the epitope iscapable of inducing a T-cell response in a subject, and induce B-cellsto produce antibodies against the entire antigen of interest. Epitopesas used in describing this invention, include any determinant on anantigen that is responsible for its specific interaction with anantibody molecule or fragment thereof. Epitopic determinants usuallyconsist of chemically active surface groupings of molecules such asamino acids or sugar side chains and have specific three-dimensionalstructural characteristics as well as specific charge characteristics.To have immunogenic properties, a protein or polypeptide generally iscapable of stimulating T-cells. However, a carrier protein that lacks anepitope recognized by a T-cell may also be immunogenic.

By selecting a carrier protein which is known to elicit a strongimmunogenic response, a diverse population of subjects can be treated bya PCMV described herein. The carrier protein desirably is sufficientlyforeign to elicit a strong immune response to the vaccine. Typically,the carrier protein used is a molecule that is capable of impartingimmunogenicity to the antigen of interest. In a desirable embodiment, acarrier protein is one that is inherently highly immunogenic. Thus acarrier protein that has a high degree of immunogenicity and is able tomaximize antibody production to the antigens complexed with it isdesirable.

Various carrier proteins of the invention include, e.g., toxins andtoxoids (chemical or genetic), which may or may not be mutant, such asanthrax toxin, PA and DNI (PharmAthene, Inc.), diphtheria toxoid(Massachusetts State Biological Labs; Serum Institute of India, Ltd.) orCRM 197, tetanus toxin, tetanus toxoid (Massachusetts State BiologicalLabs; Serum Institute of India, Ltd.), tetanus toxin fragment Z,exotoxin A or mutants of exotoxin A of Pseudomonas aeruginosa, bacterialflagellin, pneumolysin, an outer membrane protein of Neisseriameningitidis (strain available from the ATCC (American Type CultureCollection, Manassas, Va.)), Pseudomonas aeruginosa Hcp1 protein,Escherichia coli heat labile enterotoxin, shiga-like toxin, human LTBprotein, a protein extract from whole bacterial cells, and any otherprotein that can be cross-linked by a linker. Desirably, the carrierprotein is the cholera toxin B subunit (available from SBL Vaccin AB),diphtheria toxin (Connaught, Inc.), tetanus toxin Fragment C (availablefrom Sigma Aldrich), DNI, or beta-galactosidase from Escherichia coli(available from Sigma Aldrich). Other desirable carrier proteins includebovine serum albumin (BSA), P40, and chicken riboflavin. (Unlessotherwise indicated, the exemplary carrier proteins are commerciallyavailable from Sigma Aldrich.) Other exemplary carrier proteins are MAPs(multi-antigenic peptides), which are branched peptides. By using a MAP,cross-linking density is maximized because of multiple branched aminoacid residues. An exemplary amino acid that can be used to form a MAPis, but is not limited to, lysine.

Both BSA and keyhole limpet hemocyanin (KLH) have commonly been used ascarriers in the development of vaccines when experimenting with animals.Carrier proteins which have been used in the preparation of therapeuticvaccines include, but are not limited to, a number of toxins ofpathogenic bacteria and their toxoids. Examples include diphtheria andtetanus toxins and their medically acceptable corresponding toxoids.Other candidates are proteins antigenically similar to bacterial toxinsreferred to as cross-reacting materials (CRMs). Carrier proteins of theinvention may also include any protein not derived from humans and notpresent in any human food substance.

In desirable embodiments of the invention, proteins that form ring-likestructures are used for PCMV production. Such proteins include the Hcp1protein of Pseudomonas aeruginosa, the nontoxic “B subunits” of choleratoxin, the heat-labile enterotoxin of Escherichia coli, and shiga-liketoxin. Such ring-like protein complexes can form “beads on a string”where the linear PS chains penetrate the central channel of thesering-shaped protein complexes. After protein cross-linking, suchcomplexes are predicted to be particularly stable. Structural data ofthe proteins suggest these central channels are large enough for PSchains to enter easily. For example, the central channel of the Hcp1hexameric ring is 42 Angstoms which is wide enough to easily accommodateseveral polysaccharide chains of 5.5 Angstoms in width (Mougous et al.,Science 312(5779):1526-1530, 2006). Alternatively, protein rings may beassembled around the PS (e.g., from subunits of a monomeric carrierprotein that naturally assemble into rings under particular physicalchemical conditions). Such monomeric proteins that can assemble intorings are known in the art and include, for example, pneumolysin (Walkeret al., Infect. Immun. 55(5):1184-1189, 1987; Kanclerski and Mollby, J.Clin. Microbiol. 25(2):222-225, 1987), listeriolysin 0 (Kayal andCharbit, FEMS Microbiol. Rev. 30:514-529, 2006; Mengaud et al., Infect.Immun. 55(12):3225-3227, 1987), DNI, anthrax PA, Hcp1, cholera toxin Bsubunit, shiga toxin B subunit, Flagellin, and numerous relatedmolecules known in the art and made by various microorganisms.

In another desirable embodiment, Toll-like receptor (TLR) agonists areused as carrier proteins. Toll-like receptor (TLR) activation isimportant in shaping the adaptive immune response and may play a role inaffinity maturation of the antibody response, isotype switching, andimmunological memory. Flagellin (FLA) of Vibrio cholerae is a TLRagonist. Over 20 mgs of FLA protein has been purified from recombinantEscherichia coli and shown to be a potent TLR activator in the IL-6macrophage induction assay described herein. In addition, awell-conserved Streptococcus pneumoniae protein called “Pneumolysin” hasalso been shown to activate TLR4 and, additionally, is a protectiveantigen. Thus, this protein can also be used as a PCMV carrier protein.

Further, outer membrane protein (OMP) mixtures (e.g., the OMPs ofNeisseria meningitidis) are used as the carrier protein for HIBconjugate vaccine produce by Merck and protein extracts from wholeStreptococcal pneumoniae bacterial cells have been shown to be at leastpartially protective in animal infection model. In desirable embodimentsof the invention, these protein mixtures are the source of PCMV carrierprotein.

In a desirable embodiment, the PCMV method is used with a carrierprotein that has, e.g., at least 2 lysine residues or other residuesthat are unblocked and that can be cross-linked by chemicalmodification. In other desirable embodiments, the carrier protein is amultimer (e.g., one containing at least 5 subunits). Desirably, themultimer is a homomultimer.

In another embodiment, DNI is used as the carrier protein because it isnontoxic leaving no need to detoxify the protein before use.Furthermore, the use of DNI is desirable because DNI may also induce aprotective immune response to B. anthracis, in addition to theprotective immune response to the antigen of interest. Also, DNI has nointernal disulfide bonds. Such bonds are susceptible to borohydridereduction, which could denature the protein and result in loss ofepitopes that induce anthrax toxin neutralizing antibody.

Antigens of Interest

The vaccine compositions of the invention and methods of making andadministering such vaccines can be used for any antigen of interest,e.g., a polysaccharide, polyalcohol, or poly amino acid. Desirably, theantigen of interest carries no primary groups that can be destroyed bythe chemical reactions employed by the method of making vaccines, e.g.,the denaturing of an antigen caused by the destruction of antigendisulfide bonds by borohydride reduction. Exemplary antigens of interestinclude organic polymers such as polysaccharides (e.g., polysaccharideshaving at least 18 residues), phosphopolysaccharides, polysaccharideswith amino sugars with N-acetyl substitutions, polysaccharidescontaining sulfonylated sugars, other sulfate-modified sugars, orphosphate-modified sugars, polyalcohols, poly amino acids, teichoicacids, O side chains of lipopolysaccharides. Exemplary antigens ofinterest also include capsular organic polymers including thosesynthesized by microbes, e.g., bacteria, fungi, parasites, and viruses,and then purified from such a biological source using standard methods.Exemplary antigens of interest include microbial capsular organicpolymers including those purified from bacterial organisms such asBacillus species (including B. anthracis) (Wang and Lucas, Infect.Immun. 72(9):5460-5463, 2004), Streptococcus pneumoniae (Bentley et al.,PLoS Genet. 2(3):e31, Epub 2006; Kolkman et al., J. Biochemistry123:937-945, 1998; and Kong et al., J. Med. Microbiol. 54:351-356,2005), Shigella (Zhao et al., Carbohydr. Res. 342(9):1275-1279, Epub2007), Haemophilus influenzae, Neisseria meningitidis, Staphylococcusaureus, Salmonella typhi, Streptococcus pyogenes, Escherichia coli (Zhaoet al., Carbohydr. Res. 342(9):1275-1279, Epub 2007), and Pseudomonasaeruginosa, and fungal organisms such as Cryptococcus and Candida, aswell as many other microorganisms (see, e.g., Ovodov, Biochemistry(Mosc.) 71(9):937-954, 2006; Lee et al., Adv. Exp. Med. Biol.491:453-471, 2001; and Lee, Mol. Immunol. 24(10):1005-1019, 1987).Exemplary antigens of interest also include polymers that do not occurin nature and thus are non-biological in origin.

Vaccine Compositions

The vaccines of the invention, including PCMVs, may be used incombination, for example, in pediatric vaccines. In addition, thevaccines of the invention may be used to vaccinate against, for example,Pneumococcus infection, Haemophilus influenzae type B (“HiB”) infection,Streptococcus (groups A and B) infection, meningococcal (e.g., Neisseriameningitides) infection, and may be used as O antigen vaccines from Gramnegative bacteria (e.g., Pseudomonas aeruginosa, Francisella tularensis,Shigella species, Salmonella species, Acinetobacter species,Burkholderia species, and Escherichia coli).

The vaccine formulation desirably includes at least one carrier protein,one or more antigen of interest, and a pharmaceutically acceptablecarrier or excipient (e.g., aluminum phosphate, sodium chloride, andsterile water). A vaccine composition may also include an adjuvantsystem for enhancing the immunogenicity of the formulation, such as oilin a water system and other systems known in the art or otherpharmaceutically acceptable excipients. A carrier/antigen complex thatis insoluble under physiological conditions is desirable to slowlyrelease the antigen after administration to a subject. Such a complexdesirably is delivered in a suspension containing pharmaceuticallyacceptable excipients. However, the carrier/antigen complex may also besoluble under physiological conditions.

Typically the vaccine is in a volume of about 0.5 mL for subcutaneousinjection, 0.1 mL for intradermal injection, or 0.002-0.02 mL forpercutaneous administration. A 0.5 ml dose of the vaccine may containapproximately 2-500 μg of the antigen entrapped with approximately 2-500μg of the carrier protein. In a desirable embodiment, in a 0.5 ml dose,approximately 10 μg of the antigen are entrapped with approximately 10μg of the carrier protein. The molar ratio of antigen to carrier proteindesirably is between 1 to 10 (e.g., 1 part antigen to 2 parts carrier or1 part antigen to 3 parts carrier) and 10 to 1 (e.g., 3 parts antigen toone part carrier or 2 parts antigen to 1 part carrier). In a desirableembodiment, the molar ratio of antigen to carrier is 1 to 1.Alternatively, the ratio by dry weight of antigen to carrier proteindesirably is between 1 to 10 and 10 to 1 (e.g., 1 to 1 by dry weight).

Because the peptides or conjugates may be degraded in the stomach, thevaccine is desirably administered parenterally (for instance, bysubcutaneous, intramuscular, intravenous, or intradermal injection).While delivery by a means that physically penetrates the dermal layer isdesirable (e.g., a needle, airgun, or abrasion), the vaccines of theinvention can also be administered by transdermal absorption.

In particular, the vaccines of the invention may be administered to asubject, e.g., by intramuscular injection, intradermal injection, ortranscutaneous immunization with appropriate immune adjuvants. Vaccinesof the invention may be administered, one or more times, often includinga second administration designed to boost production of antibodies in asubject to prevent infection by an infectious agent. The frequency andquantity of vaccine dosage depends on the specific activity of thevaccine and can be readily determined by routine experimentation.

For example, for an infant, a vaccine schedule may be three doses of 0.5ml each at approximately four to eight week intervals (starting attwo-months of age) followed by a fourth dose of 0.5 ml at approximatelytwelve to fifteen months of age. A fifth dose between four and six yearsof age may be desirable for some vaccines.

While the age at which the first dosage is administered generally istwo-months, a vaccine may be administered to infants as young as 6 weeksof age. For children who are beyond the age of a routine infantvaccination schedule, the vaccines of the invention may be administeredaccording to the following exemplary schedule. Age of first dosageDosage schedule 7-11 months of age Total of three 0.5 ml doses; thefirst two at least four weeks apart and the third at least two monthsafter the second dose 12-23 months of age Total of two 0.5 ml doses atleast two months apart 24 months to 9 One 0.5 ml dose years of age

For adults, two or more 0.5 ml doses given at internals of 2-8 week inbetween generally are sufficient to provide long-term protection. Abooster dose is desirably given every ten years to previously immunizedadults and children above eleven years of age.

The formulations may be presented in unit-dose or multi-dose containers,for example, sealed ampoules and vials and may be stored in afreeze-dried (lyophilized) condition requiring only the addition of thesterile liquid carrier immediately prior to use. Vaccines of theinvention can be formulated in pharmacologically acceptable vehicles,e.g., alum hydroxide gel, adjuvant preparation, or saline, and thenadministered, e.g., by intramuscular injection, intradermal injection,or transcutaneous immunization with appropriate immune adjuvants.

The invention also includes kits that include a vaccine described herein(e.g., a PCMV). The kits of the invention can also include instructionsfor using the kits in the vaccination methods described herein.

The efficacy of the immunization schedule may be determined by usingstandard methods for measuring the antibody titer in the subject. Ingeneral, mean antibody titers (desirably IgG titers) of approximately 1μg/ml are considered indicative of long-term protection.

The antigen/carrier protein complexes for use in the vaccinecompositions described herein are desirably between 10 nm and 100 μm indiameter. Viruses can be 100 nm in diameter and are immunogenic. Wholebacteria are 1-10 μm in diameter and are also immunogenic. A small clumpof bacteria can be about 100 μm in diameter. In particular embodiments,an antigen/carrier protein complex in a vaccine composition desirably isbetween 100 nm and 10 μm in diameter. This complex may be soluble orinsoluble.

The invention is described herein below by reference to specificexamples, embodiments and figures, the purpose of which is to illustratethe invention rather than to limit its scope. The following examples arenot to be construed as limiting.

EXAMPLES Example 1 Vaccine and Control Preparations

Capsular poly gamma-D-glutamic acid (PGA) was purchased from Vedan(Taiwan) or purified by the method of Rhie et al. (Proc. Natl. Acad.Sci. USA 100: 10925-10930, 2003). Dominant negative mutant (DNI) is amutated form of protective antigen (PA) of B. anthracis and was producedfrom Escherichia coli by the method of Benson, et al. (Biochemistry37:3941-3948, 1998). PGA and DNI protein were exhaustively dialyzedagainst 0.05M sodium phosphate buffer pH 7.4 (SP7.4) before use. The DNIstock solution contained 30 mg/ml. The PGA stock solution contained 134mg/ml. The linker glutaraldehyde was purchased from Pierce as a 25%stock solution. Protein Capsular Matrix Vaccines (PCMVs) and controlswere assembled in reactions according to the Table 1. TABLE 1 Assemblyof reactions for production of PCMV preparations 1-3 and controls 4 and5 Reaction DNI PGA dH2O 25% glutaraldehyde # ml ml ml ml Name 1 20 1 30.8 PCMV1 2 12 4 8 0.8 PCMV2 3 16 2 6 0.8 PCMV3 4 16 2 6 0 P + C control5 16 0 8 0.8 P only control

The five reactions were assembled at room temperature (22° C.) withoutglutaraldehyde. At T=0, 0.1 ml of 25% glutaraldehyde (G25) was added tothe indicated reactions. Each 30 seconds thereafter another 0.1 ml ofG25 was added and this was repeated until each indicated reaction hadreceived 0.8 ml of G25 in total. The cross-linking of DNI molecules bythe bi-functional glutaraldehyde molecules could be observedmacroscopically by the generation of varying degrees of turbidity andinsoluble “gel” like particles in the following order: most turbidityand gel formation, reactions 1>2>3>4, with reaction 5 remaining totallyclear and soluble. After 1 hour, 2 ml of 1 M sodium borohydride in 0.5 Msodium borate buffer pH 9.3 (SBH) was added to all six reactions toreduce Schiff bases formed between the amino side chains of the DNImolecules and the bi-functional glutaraldehyde molecules. Siliconeantifoam (0.01 ml) was added to each reaction to control foaming duringthis reaction. The reactions were stored at 4° C. for 72 hours. Allreactions were then dialyzed exhaustively against SP7.4, for 48 hours.Insoluble material was removed by centrifugation of the final productsand stored at 4° C. until use.

A conventional conjugate between bovine serum albumin (BSA) and PGA wassynthesized by coupling the amino groups of BSA to the carboxyl groupsof PGA using the water soluble carbodiimide, EDAC(1-ethyl-3-(3-dimethylaminopropyl) carbodiimide), as follows: 5 ml of 30mg/ml BSA in water was mixed with 1 ml of 134 mg/ml PGA in NP7.5. 50 mgof EDAC was added and the reaction was allowed to proceed at RT for 3hours. The reaction was dialyzed at 4° C. for 18 hours against SP7.4containing 1 mM glycine to block activated groups and then at 4° C. for24 hours against SP7.4 only. The final product is referred to as PGA-BSAconjugate.

After synthesis and dialysis of PCMV and control preparations themolecular state of the DNI protein was examined to confirm thatglutaraldehyde had indeed molecularly cross-linked the protein in thepresence or absence of various amounts of PGA. PCMV and controlpreparations were monitored for such cross-linking by SDS (sodiumdodecyl sulphate) polyacryamide gel electrophoresis and Western blottingwith anti-PA antiserum. As shown in FIG. 2, DNI protein migrates at 84kDa before glutaraldehyde cross-linking. PCVM1-PCMV3 (lanes 1-3) showextensive cross-linking of the DNI protein as evidenced by the migrationof bands at molecular masses greater than 220 kDa. DNI protein alonecross-linked in the absence of PGA also shows the same high molecularweight species (lane 5). In contrast, DNI mixed with PGA but not treatedwith glutaraldehyde shows bands that co-migrate with DNI or lowermolecular weight species (lane 4). Thus, the PGA preparation from Vedan(Taiwan) appeared to be contaminated with a protease active against DNI.Samples of Vedan PGA run in lane 6 however did not show high levels ofcontaminating proteins that react with the anti-PA antiserum, suggestingthat the observed bands were DNI-derived products of the variousreactions.

In addition, PGA and one or more of the pneumococcal PS as antigens isused to explore whether FLA (flagellin of Vibrio cholerae) is a bettercarrier protein than DNI in the context of PCMVs. The effect of thecarrier protein is assessed by measuring the level of IgG directedagainst PGA, and PSs achieved by immunization with these various PCMVsas well as their potency on a weight of protein basis.

PCMVs can also be made by a procedure that cross-links amino groups tocarboxy groups directly without the use of a bifunctional cross-linker.In particular, PCMVs can be made by cross-linking amino and carboxylgroups of the carrier proteins using carbodiimide chemistry. Thischemistry forms peptide bonds between primary amino groups of lysineside chains and the carboxyl groups of aspartate and glutamate sidechains. While amino groups are mostly blocked on formalin treatedtoxoids, formalin does not react with carboxyl groups at all. Thus,carbodiimide chemistry can be useful in making PCMVs using formalintoxoids that can resist glutaraldehyde cross-linking. Cross-linking isreadily detected by SDS-PAGE. The presence of high molecular weightprotein “smears” that depend on addition of a cross-linker likeglutaraldehyde is indicative of cross-linking. TABLE 2 Cross-linking ofcarrier proteins determined by SDS-PAGE analysis. Glutaraldehyde No YesYes Yes Yes Capsular Polymer −PGA −PGA +PGA +PS 6B +PS 23F BSA − + + + +Diphtheria Toxin − + + n.d. n.d. Diphtheria Toxoid − − − n.d. n.d.Tetanus Toxoid − + + n.d. n.d.+ signs indicate cross-linking was detected by SDS-PAGE,− signs indicate protein migration was unaltered from that seen in theno glutaraldehtde control.n.d.—not determined (assay not performed).

For the experiments shown in Table 2, 200 microliter reactions were donein 50 mM HEPES pH 7.5 and incubated at ambient temperature for 2 hours.The reactions were quenched with 120 mM sodium borohydride.Glutaraldehyde was added to 64 mM, bovine serum albumin (BSA) was usedat 15 mg/ml, diphtheria toxin, diphtheria toxoid, and tetanus toxoidwere used at about 5 mg/ml, PGA was added at 13.4 mg/ml, pneumo PS type6B and 23F were added at 4 mg/ml.

As shown in Table 2, some formalin treated proteins (e.g., diphtheriatoxoid) do not cross-link well with glutaraldehyde and, therefore,require other cross-linking chemistry for use in PCMV preparation.Others, like tetanus toxoid, can be glutaraldehyde cross-linked but notto the same extent as unmodified proteins such as diphtheria toxin andbovine serum albumin.

Example 2 Immunization and Analysis of Anti-DNI and Anti-PGA ImmuneResponses

The soluble products of the 5 reactions described in Table 1 wereadjusted to the same protein concentration based on their absorbance at280 nm. Approximately 5-7 week old BALB/c mice from Charles River wereused in all immunization studies described in FIG. 2. Mice wereimmunized with PCMV vaccines 1-3 and antigen preparation controls 4 and5 at a dose of 20 Hg of DNI protein by intraperitoneal injection on day0. All mice were bled on day 7 and then boosted with the same size dosesof antigen preparations on day 10. The mice were bled again on day 17and then boosted again on day 20. Mice were bled again on day 30 atwhich time they were sacrificed. Serum from blood samples was collectedafter clotting occurred and stored at −20° C. Enzyme-linkedimmunosorbent assay (ELISA) was used to assay for the level of anti-PGAand anti-DNI serum antibodies. In brief, Immulon 2HB ELISA (VWR)microtiter dishes were coated with either BSA-PGA or DNI in 0.1 M sodiumcarbonate buffer, pH 9.6 at 0.5 μg/well in a volume of 100 μl/well.After overnight incubation at 4° C., antigen-coated plates were blockedby incubation with 3% BSA (w/v) in TBS-0.1% Tween (TBST) for 1 hour atroom temperature or overnight at 4° C. Serum samples pooled from groupsof four mice from each time point post-boost were serially diluted inTBST and added to antigen-coated plates and incubated for at least 1hour. Anti-DNI and anti-PGA antibody responses were determined usingrabbit anti-serum against mouse IgG or IgM conjugated to alkalinephosphatase (Zymed). The substrate p-nitrophenyl phosphate (PNPP) wasadded to each well and the absorbance at 405 nm was determinedspectrophotometrically for each reaction. Data are reported as thereciprocal endpoint titer, defined as the maximum dilution to obtain anOD₄₀₅ reading that is two standard deviations above that of the negativecontrol.

ELISA assays were used to measure the IgM and IgG specific anti-DNI andanti-PGA immune responses in mice immunized with the three PCMVpreparations 1-3 and the two antigen control preparations 4 and 5 (FIGS.3-5). As shown in FIG. 3, the DNI protein was highly immunogenic in allpreparations except control preparation 4 which was not cross-linkedwith glutaraldehyde (no glut). However, these DNI-specific immuneresponses were exclusively IgG-based. While no anti-DNI IgM was detectedeven at day 7 of the immunization, a significant anti-DNI IgG responsecould be detected in mice immunized with PCMV preparations by day 17 andthose immunized with cross-linked DNI only (preparation 5). A strongbooster response was noted against DNI on day 30 with all preparationsincluding preparation 4.

Anti-PGA IgM responses showed a pattern that was typical of a capsularpolymer (FIG. 4). The control preparation 4 generated a detectableanti-PGA IgM response on day 7, but this response was not boosted on day17 or day 30. All PCMV preparations induced an anti-PGA IgM response onday 7 and then exclusively generated even stronger anti-PGA IgMresponses on days 17 and 30. As expected the control preparation 5(cross-linked DNI only) did not generate either an IgM- or IgG-basedanti-PGA response. In marked contrast, PCMV1-3 (preparations 1-3jgenerated strong IgG-based anti-PGA responses that were apparent on day17 and then clearly boosted on day 30 (FIG. 5). The IgG-based anti-PGAresponses seen for PCMV1-3 were clearly similar to the reportedresponses to PGA observed for a conventional PGA-DNI conjugate vaccineas reported by Aulinger et al. (Infect. Immun. 73:3408-3414, 2005) andto a PA-PGA conjugate vaccine described by Rhie et al. (Proc. Natl.Acad. Sci. USA 100:10925-10930, 2003). Thus PCMV vaccines #1, #2 and #3all performed as well as conventional conjugate PGA vaccines by inducingIgG responses to capsular PGA, a known T-independent, protective antigenof B. anthracis (Wang et al., Infect. Immun. 72:5460-5463, 2004). Thecontrol preparation 5 which contained DNI (not cross-linked) mixed withPGA induced no detectable IgG against PGA indicating DNI does not act asa TLR ligand in stimulating IgG anti-PGA responses in PCMV preparations1-3. This result also confirms observations in the literature that PGAis a T-cell independent immunogen of low immunogenicity unless it iscoupled to protein through covalent bonds (Rhie et al., Proc. Natl.Acad. Sci. USA 100:10925-10930, 2003). The PCMV method apparentlyconverts PGA to a T-cell dependent immunogen despite the fact that themethod does not result in cross-linking of the DNI protein directly toPGA molecules.

These data support that the PCMV method can produce immunogens withproperties similar to conventional conjugate vaccine. The PGA PCMV wasreadily made using the methods described herein and was found to induceimmune responses typical of PGA-protein conjugate vaccines. Thesmall-scale reactions detailed in Table 1 produced enough PCMV toimmunize 1000 mice based on the dosage scheme outlined in FIG. 3. Thepresent data support that PCMV made from PGA and DNI can be used as avaccine to protect against anthrax caused by Bacillus anthracis.

Example 3 Generation and Characterization of Additional PCMVs

The PCMV technology can be applied to capsular antigens of variousstructures and ionic charges. 23 types of Streptococcus pneumonia PS'swere purchased from the American Type Culture Collection (ATCC) and aremanufactured by Merck, Inc. These PS vary widely in their molecularstructure and include PS's that are strongly anionic, partiallycationic, neutral in charge, phosphorylated, linear, have branchingstructures, and modified in various other ways. In preliminaryexperiments, a subset of these PS that correspond to the seven capsulartypes in the Wyeth product Prevnar (4, 6B, 9V, 14, 18C, 19F, and 23F)were assayed for their ability to induce IL-6 production by mousemacrophages. Type 4 PS was active in this assay; lipopolysaccharide(LPS) was the control for a TLR agonist. Other PSs (e.g., type 3), PGA,and O antigen PS from F. tularensis as well as a PCMV vaccine made fromPGA-DNI and a non-cross-linked control were also assayed. Thisexperiment showed that Type 3 pneumococcus PS, and to a lesser extentPGA, was also contaminated with a TLR agonist. The PS from F. tularensisand the PCMV were comparably clean in the assay. Phenol extraction andethanol precipitation could “clean up” (remove residual unknown TLRagonists) S. pneumoniae PS type 3 after two consecutive treatments.Accordingly, six S. pneumoniae PSs and the F. tularensis 0 antigen PSwere found to be clean for IL6 production and these have been exploredin experiments described herein.

PCMVs for the seven PS found to be clean for WL6 production have beensynthesized using DNI as the carrier protein by a method analogous tothat described in Example 1. Preliminary immunogenicity assays suggestthat all seven PCMVs were immunogenic to varying degrees. A DNI-based“monovalent” PCMV for S. pneumoniae PS14 (14-PCMV) was found to inducehigh titers of anti-PPS14 IgG that boosted significantly after the thirdimmunization. Remarkably, the same immune response was seen when 14-PCMVwas mixed with the other six PCMVs to make a “cocktail” immunogen.Because Prevnar® is an alum absorbed “adjuvanted” vaccine, whether thehexavalent PCMV cocktail could also be absorbed to the alum adjuvant wasdetermined. The results of an immuno assay that qualitatively measuresthe amount of S. pneumoniae PS absorbed to alum after exposure to PCMVor to a control mixture of the same PSs mixed with DNI protein but notglutaraldehyde cross-linked showed that much more PS absorbed to alum inthe context of a PCMV than the control (PS+DNI protein un-cross-linked)(as indicated by the higher level of immunoreactivity for the PCMV whichdilutes out further in the immunoassay).

Immunization of mice was used to assess the immunogenicity of theheptavalent PCMV with or without absorption to alum adjuvant. Alumadjuvant improved the kinetics of the immune response to PS14, inducingIgG against this PS 7 days sooner than non-adjuvanted vaccine. However,the heptavalent PCMV was more immunogenic in the absence of alum thanthe control non-cross-linked PS+DNI combination was in the presence ofalum. This result confirms that the PCMV procedure renders PSs moreimmunogenic to mice and supports that the PCMV procedure can be used tomake cocktails of antigens that perform immunologically like cocktailsof conjugate vaccines.

In additional experiments phenol extraction and ethanol precipitation isused to remove contaminating TLR agonists from the 23 pneumococcuspolysaccharide commercial preparations. Removal of the contaminants isconfirmed by testing the treated PSs for induction of IL-6 by peritonealmacrophages by standard methods. PSs that are devoid of IL-6 inductionactivity are used for production of PCMV. Other polysaccharides that areused in PCMVs include an 0 antigen PS purified from F. tularensis andPGA capsule from B. anthracis. A total of 25 capsular types are examined(23 pneumococcal types, and one each of the tularemia and anthraxtypes). Each of the 25 capsular types is used to make a PCMV using theDNI protein, essentially by the method described in Example 1. A one toone ratio of PS to protein is used (approximately 1:1 by dry weight) forthese initial PCMV preparations. Each preparation is characterized bySDS-PAGE for evidence of protein cross-linking which has correlatedperfectly with the immunogenicity of various PCMV preparations inpreliminary experiments. For some capsular types (e.g., 6B and 23F),other carrier proteins are used to make PCMVs. For these same capsulartypes (e.g., 6B and 23F), an alternative cross-linking chemistry can beused. All PCMV preparations that show evidence of protein cross-linking(e.g., in SDS-PAGE), are tested for their immunogenicity.

For example, ten different PCMVs using five different matrix proteinsand two different antigens are made as follows. The selection of thefive matrix proteins is based on their current use in FDA-licensedvaccines or other properties that allow them to serve as tracers formeasuring the stability of PCMV preparations. The following matrixproteins are used (1) cholera toxin B subunit (available from SBL VaccinAB), (2) diphtheria toxin, (3) tetanus toxin Fragment C, “Frag C”(available from Sigma Aldrich), (4) DNI, and (5) beta-galactosidase fromEscherichia coli (available from Sigma Aldrich). As capsular antigenspoly-D-glutamic acid from Bacillus anthracis and Streptococcuspneumoniae capsule type 14 (Suarez et al., Appl. Environ. Micobiol.67:969-971, 2001) are used. Both of these capsular antigens are highlyimmunogenic when used with DNI as a matrix protein in correspondingPCMVs. Each capsule antigen is combined with each of the five selectedmatrix proteins to produce 10 distinct PCMVs.

PCMVs can be tested for their ability to induce, in mice, isotypeantibody switching to IgG as is observed in conventional conjugatevaccines. All antigens can be absorbed to alum and then typically groupsof 5 mice per PCMV preparation are used. Mice are pre-bled to obtainbaseline immune responses to the test antigens. Mice are then immunizedthree times (at day 0, 7, 14) by standard IP injection protocol andblood is collected at days 10, 20, 30, and 60 days post primaryimmunization. Mouse sera are analyzed by standard ELISA assay for IgGagainst the PS and carrier proteins used. In these experiments, controlgroups of mice immunized with only PS are included to assess the abilityof various PCMV preparations to induce anti-PS IgG compared with thenonconjugated PS which should be poorly- or non-immunogenic. PromisingPCMVs (i.e., PCMVs that induce high levels of IgG against PSs) undergomore careful immunological analysis which seeks to establish thekinetics and dose response aspects of the immune response to the PCMV inmice.

Alternatively, promising PCMVs and their corresponding controls can besent to commercial vendors for production of rabbit anti-sera. Similarimmuno assays are performed to assess the immunogenicity, class ofantibody induced, and kinetics of immune response in rabbits. In theseexperiments the control is the commercial product Prevnar® which is analum absorbed mixture of 7 different conventional conjugate PS vaccinescoupled to CRM197, the nontoxic mutant protein related to diphtheriatoxin.

The functionality of the antibody responses induced with PCMVs can beassessed. For example, functionality can be assessed by measuring theability of the anti-PS antibody to opsonize encapsulated S. pneumococcusand lead to bacterial killing after phagocytosis by macrophages.Protection of animals from lethal challenge with S. pneumococcus isanother way to demonstrate the efficacy of the vaccine in PCMV immunizedanimals.

Example 4 Comparison to PCMVs to Prevnar®

The relative cleanliness of S. pneumoniae polysaccharides (pps) 6B, 14,and 23F obtained from ATCC via Merck or directly from Serum Institute ofIndia (SII) was determined. IL-6 expression was used as an indicator ofthe cleanliness of a pps and LPS was used as a positive “dirty” control.As shown in FIG. 9A, Merck pps 6B, 14, and 23F are clean, while, asshown in FIG. 9B, pps 6B from SII is “dirty.” As shown in FIG. 10,treatment 2 (one hour incubation at 80° C. in 1M NaOH) cleans up SII pps6B. Clean pps 6B is used for the comparison of conjugate and PCMVimmunological properties. As shown in Table 3, the contaminant is notLPS. TABLE 3 Assay for Endotoxin Levels of PolysaccharidesPolysaccharides Endotoxin Units/mg Polysaccharide SII pps 6B - notreatment 0.75 SII pps 23F - no treatment 0.85 SII pps 23F - treatment 20.24 Merck pps various - no treatment 0.1-0.4

FIGS. 11 and 13 show that Prevnar® (which is alum adjuvated) induces IgGantibodies against pps 6B and that the IgG response from alum adjuvatedPCMVs (BSA and pps 6B; Diphtheria toxin and pps 6B; Diphtheria toxoidand pps 6B; and Tetanus toxoid and pps 6B) is better than that observedwith Prevnar®. Similarly, as shown in FIG. 12, the IgM response to alumadjuvated PCMVs is similar to that see for Prevnar®.

In addition, for pps 14 (the most immunogenic pps in Prevnar®), as shownin FIGS. 14-16, alum adjuvated PCMVs containing Diphtheria toxoid andpps 14 or Tetanus toxoid and pps 14, are approximately equivalent toPrevnar® in inducing an IgG response.

Example 5 Multivalent PCMVs

Multivalent immunogens were produced using the PCMV method by mixingchemically different capsular organic polymers together beforecross-linking the DNI carrier protein with glutaraldehyde (“one potsynthetic reaction”). Trivalent immunogens of this sort were made fromthree organic polymers—PGA, alginate and dextran—using DNI as thecarrier. These trivalent vaccines were immunogenic and generated immuneresponses against the three capsular organic polymers as shown by pooledserum IgM analyzed pre-immunization and after 30 days (FIG. 6), theantigen-specific serum IgG antibody titer 60 days post immunization(FIG. 7), and the anti-PS serum antibody titer 128 days postimmunization (FIG. 8). As also shown in FIGS. 6-8, the monovalentalginate PCMV preparations also generated an immune response in mice.Multivalent PCMV immunogens can also be formulated by mixing specificPCMVs that are synthesized separately and then mixed together at the endto produce a “cocktail” vaccine.

All patents, patent applications, patent application publications, andother publications cited or referred to in this specification are hereinincorporated by reference to the same extent as if each independentpatent, patent application, patent application publication orpublication was specifically and individually indicated to beincorporated by reference.

1. A vaccine composition comprising an antigen of interest and a carrierprotein, wherein (i) no more than 50% of said antigen of interest iscross-linked to said carrier protein and (ii) wherein said antigen isentrapped with said carrier protein to form a complex.
 2. The vaccinecomposition of claim 1, wherein said complex has a diameter of between10 nm and 100 μm.
 3. The vaccine composition of claim 2, wherein saidcomplex has a diameter of about 100 nm to 100 μm.
 4. The vaccinecomposition of claim 2, wherein said complex has a diameter of about 100nm to 10 μm.
 5. The vaccine composition of claim 1, wherein saidcomplex, when administered to a mammal, elicits a T-cell dependentimmune response in said mammal.
 6. The vaccine composition of claim 1,wherein the molar ratio of said antigen to said carrier protein isbetween 1 to 10 and 10 to
 1. 7. The vaccine composition of claim 1,wherein said carrier protein is a multimer.
 8. The vaccine compositionof claim 7, wherein said multimer comprises at least 5 subunits.
 9. Thevaccine composition of claim 7, wherein said multimer is a homomultimer.10. The vaccine composition of claim 1, wherein said carrier protein iscovalently linked to at least one other carrier protein.
 11. The vaccinecomposition of claim 10, wherein said covalent linkage comprises apeptide bond between a primary amino group of a lysine side chain and acarboxy group of an aspartate or glutamate side chain.
 12. The vaccinecomposition of claim 10, wherein said covalent linkage comprises acompound of the formula

wherein R_(n) is a linear or branched alkyl of 1 to 12 carbon atoms, alinear or branched heteroalkyl of 1 to 12 atoms, a linear or branchedalkene of 2 to 12 carbon atoms, a linear or branched alkyne of 2 to 12carbon atoms, an aromatic residue of 5 to 10 carbon atoms, a cyclicsystem of 3 to 10 atoms, —(CH₂CH₂O)_(q)CH₂CH₂— in which q is 1 to 4, ora chemical bond linking two aldehyde groups.
 13. The vaccine compositionof claim 10, wherein said covalent linkage comprises glutaraldehyde,m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide, orbis-biazotized benzidine.
 14. The vaccine composition of claim 10,wherein said covalent linkage comprises a bifunctional cross-linker. 15.The vaccine composition of claim 14, wherein said bifunctionalcross-linker is glutaraldehyde, bis[sulfosuccinimidyl]suberate, ordimethyl adipimidate.
 16. The vaccine composition of claim 1, whereinsaid carrier proteins are non-covalently linked.
 17. The vaccinecomposition of claim 16, wherein said non-covalent linkage comprises ahydrophobic interaction, ionic interaction, van der Waals interaction,or hydrogen bond.
 18. The vaccine composition of claim 1, wherein saidcarrier protein is diphtheria toxin or a mutant thereof, diphtheriatoxoid, tetanus toxin or a mutant thereof, tetanus toxoid, Pseudomonasaeruginosa exotoxin A or a mutant thereof, cholera toxin B subunit,tetanus toxin fragment C, bacterial flagellin, pneumolysin, an outermembrane protein of Neisseria menningitidis, Pseudomonas aeruginosa Hcp1protein, Escherichia coli heat labile enterotoxin, shiga-like toxin,human LTB protein, pneumolysin, listeriolysin O (or related proteins), aprotein extract from whole bacterial cells, the dominant negative mutant(DNI) of the protective antigen of Bacillus anthracis, or Escherichiacoli beta-galactosidase.
 19. The vaccine composition of claim 18,wherein said whole bacterial cells are Pseudomonas aeruginosa orStreptococcal cells.
 20. The vaccine composition of claim 18, whereinsaid bacterial flagellin is the Vibrio cholerae flagellin protein. 21.The vaccine composition of claim 18, wherein said shiga-like toxin isthe Shigella SltB2 protein.
 22. The vaccine composition of claim 18,wherein said carrier protein is pneumolysin.
 23. The vaccine compositionof claim 18, wherein said carrier protein is listeriolysin O.
 24. Thevaccine composition of claim 18, wherein said carrier protein isdiphtheria toxin.
 25. The vaccine composition of claim 18, wherein saidcarrier protein is diphtheria toxoid.
 26. The vaccine composition ofclaim 18, wherein said carrier protein is tetanus toxin.
 27. The vaccinecomposition of claim 18, wherein said carrier protein is tetanus toxoid.28. The vaccine composition of claim 1, wherein said antigen of interestis a polysaccharide, a polyalcohol, or a poly amino acid.
 29. Thevaccine composition of claim 28, wherein said polysaccharide comprisesat least 18 residues.
 30. The vaccine composition of claim 28, whereinsaid polysaccharide is a Streptococcus pneumoniae polysaccharide,Francisella tularensis polysaccharide, Bacillus anthracispolysaccharide, Haemophilus influenzae polysaccharide, Salmonella typhipolysaccharide, Salmonella species polysaccharide, Shigellapolysaccharide, or Neisseria meningitidis polysaccharide.
 31. Thevaccine composition of claim 30, wherein said Streptococcus pneumoniaepolysaccharide is capsular type 3, 4, 6B, 7A, 7B, 7C, 7F, 9A, 9L, 9N,9V, 12A, 12B, 12F, 14, 15A, 15B, 15C, 15F, 17, 18B, 18C, 19F, 23F, 25A,25F, 33F, 35, 37, 38, 44, or
 46. 32. The vaccine composition of claim30, wherein said Francisella tularensis polysaccharide is O antigen. 33.The vaccine composition of claim 1, wherein said antigen of interest isa microbial capsular polymer.
 34. The vaccine composition of claim 33,wherein said microbial capsular polymer is poly-gamma-D-glutamic acidfrom Bacillus anthracis.
 35. The vaccine composition of claim 1, whereinsaid antigen of interest is an organic polymer consisting of monomershaving at least three atoms, wherein each of said atoms is independentlyselected from the group consisting of carbon, oxygen, hydrogen,phosphate, nitrogen, and sulfate.
 36. The vaccine composition of claim35, wherein said organic polymer is derived from a microbe.
 37. Thevaccine composition of claim 35, wherein said organic polymer does notoccur in nature.
 38. The vaccine composition of claim 1, wherein saidvaccine composition further comprises a second antigen of interest. 39.The vaccine composition of claim 38, wherein said vaccine compositionfurther comprises a third antigen of interest.
 40. A method of making avaccine composition comprising (i) mixing an antigen of interest with acarrier protein to form a mixture of said antigen and said carrierprotein and (ii) entrapping said antigen of interest with said carrierprotein, wherein no more than 50% of said antigen of interest iscross-linked to said carrier protein in said vaccine composition.
 41. Amethod of making a vaccine composition comprising (i) mixing an antigenof interest with a carrier protein and (ii) adding a linker thatcross-links said carrier protein, wherein no more than 50% of saidantigen of interest is cross-linked to said carrier protein in saidvaccine composition.
 42. A method of vaccinating a subject against aninfectious agent, said method comprising administering a vaccinecomposition of claim 1 to a subject in an amount sufficient to inducethe production of antibodies in said subject.